GE HealthCare Technologies (GEHC) 10-K risk factor changes: FY2024 vs FY2023

These risks relate to our [removed: business,] [added: business; competition;] the healthcare [removed: industry,] [added: industry;] data [removed: privacy,] [added: privacy and cybersecurity;] laws [added: surrounding quality, regulation,] and [removed: regulations,] [added: compliance; geopolitical megatrends;] financing and capital markets [removed: activities, our Spin-Off from GE,] [added: activities; and] our common [removed: stock, and the securities market.][added: stock.]

- We operate in highly competitive markets, competition may increase in the future, and our industry may be disrupted, requiring us to lower prices or resulting in a loss of market [removed: share.][added: share, and our inability to successfully complete strategic transactions could adversely affect our business.]

[removed: - Our] [added: Our] inability to manage our supply chain or obtain supplies of components or raw materials has restricted, and could continue to restrict, the manufacturing of products, cause delays in delivery, or significantly increase our [removed: costs.][added: costs, and our use of third parties in various markets and their actions or inactions could affect our business.]

[removed: - Any] [added: Any] interruption in the operations of our [removed: manufacturing] facilities, or our [removed: suppliers’] [added: suppliers’, customers’,] or [removed: customers’] [added: third-party providers’] facilities, may impair our ability to deliver products or provide [removed: services.][added: services.]

[removed: - If] [added: If] we are unable to attract or retain key personnel and qualified employees or maintain relations with our employees, unions, and other employee [removed: representatives] [added: representatives,] it could adversely affect our [removed: business.][added: business.]

[removed: - Increased] [added: Increased] cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted [removed: computer] [added: cyber] crimes pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our [removed: business.][added: business.]

[removed: - We] [added: We] are subject to stringent privacy laws and information security [removed: policies and regulations.][added: regulations.]

- Our increasing focus on and investment in cloud, [removed: edge,] [added: edge computing,] AI, and software offerings present risks to our business.

[removed: - We] [added: We] are subject to anti-kickback and false claims [removed: laws,] [added: laws (including as these laws relate to off-label promotion of products)] and failure to comply with these laws could adversely affect our [removed: business.][added: business, including via sanctions and conditions on business activity.]

- Efforts by public and private payers to control [removed: increases in] [added: the growth of] healthcare costs may lead to lower reimbursements or increased utilization controls related to the use of our products by healthcare providers, which may affect the price of and demand for our products, services, or solutions.

- [removed: We] [added: In addition to potential litigation, arbitration, and governmental proceedings, we] are exposed to risks associated with product liability claims that have been and may be brought against us or as a result of the actions or inactions of our customers or third parties that are outside of our control.

- Global geopolitical [removed: and economic] instability, [removed: as well] [added: such] as continuing uncertainties and challenging conditions in regional [removed: economies,] [added: economies and global economic instability, such as public health crises, have and] could [added: in the future] adversely affect our [removed: business.][added: business, customers, and suppliers.]

- Our business operations are [added: tightly regulated by the U.S. FDA and equivalent global agencies and are] subject to extensive laws and regulations, [added: including the Foreign Corrupt Practices Act (the “FCPA”), similar anti-corruption] and [added: anti-bribery laws, anti-kickback and false claims laws, antitrust and competition laws, and stringent privacy laws and information securities regulations, and applicable tax laws and] any changes thereto or violations thereof could have a material adverse effect on our business.

- Increasing attention to ESG matters, including environmental, health, and safety (“EH&S”) matters, may impose additional costs [removed: on our business] and expose us to new risks.

- [removed: Our level of indebtedness, as well as our general ability to comply] [added: Complying] with [removed: covenants] [added: our requirements] under our debt [removed: instruments,] [added: instruments] could adversely affect our business, results of operations, cash flows, and financial condition.

- the introduction of new or more affordable products or product enhancements by competitors, including products that could substitute for our [removed: products;][added: products or reprocessed products or generic versions when our proprietary products lose their patent protection;]

- cost of production or delivery, whether due to geographic location, currency fluctuations, taxes, [added: tariffs,] duties, or otherwise, which may enable our competitors to offer greater discounts or lower prices;

- the strengthening of independent service organizations (“ISOs”) [added: (third-party entities that specialize in the repair] and [added: maintenance of medical devices produced by original equipment manufacturers (“OEMs”), including us) and] companies specializing in one or more of our operating segments or offerings;

[removed: As an] [added: For] example, [removed: the Chinese government has instituted] policies in [added: countries such as China and Russia that require] the [removed: last several years] [added: purchase of locally manufactured products or] that are favorable to locally-based [removed: manufacturers] [added: manufacturers,] and [removed: that] [added: our ability or decision to meet the requirements of such policies,] may [added: affect customer purchasing decisions and may] have an adverse effect on our business, operations, or financial results.

Any of these [removed: competitive] factors could adversely affect our pricing, margins, and market share and have a material adverse effect on our business results, cash flows, financial condition, or prospects.

Our business dealings [added: also] involve [removed: third-party partners] [added: other third parties] such as distributors, dealers, wholesalers, packagers, resellers, [removed: suppliers,] agents, collaboration partners, sub-contractors, and others.

In turn, these [added: third] parties may use sub-parties.

Such dealings expose us to known and unknown risks, including risks related to economic, political, and regulatory environments; performance and quality control; business continuity in the event of [removed: termination;] [added: termination or other events;] conflicts of interest; [added: cybersecurity events;] and violations of regulations and laws, including anti-corruption laws, by these third parties or their sub-parties.

We cannot control the day-to-day practices of [removed: our third-party partners] [added: these third parties] and cannot guarantee they will comply with our quality standards, [added: contractual requirements,] applicable law, and company policies regarding compliance with regulatory and legal requirements.

Successful growth through acquisitions depends upon our ability to identify suitable acquisition targets or assets, conduct due diligence, negotiate transactions on favorable terms, and ultimately complete such transactions and integrate the acquired target or asset [removed: successfully, and will be subject, in certain circumstances, to the consent of GE under the Tax Matters Agreement, as discussed in “Risks Relating to Our Spin-Off from GE.”][added: successfully.]

In addition, we also regularly evaluate a variety of other potential strategic transactions, including equity and other investments; strategic alliances that could further our strategic business objectives; [removed: or] [added: and] disposition of non-core assets.

Equity and other investments and strategic alliances pose additional risks, as we could share ownership in both public and private companies [removed: and] [added: and,] in some [removed: cases] [added: cases,] management responsibilities with one or more other parties whose objectives for the alliance may diverge from ours over [removed: time,] [added: time;] who may not have the same priorities, strategies, or resources as we [removed: do,] [added: do;] or whose interpretation of applicable policies may differ from our own.

[removed: Our] [added: - Our] inability to manage our supply chain or obtain supplies of components or raw [removed: materials] [added: materials, as well as any interruption in the operations of our facilities, our suppliers’, customers’, or third-party providers’ facilities,] has restricted, and could continue to restrict, the manufacturing of products, cause delays in delivery, [added: impair our ability to deliver products] or [added: provide services or] significantly increase our [removed: costs.][added: costs.]

[removed: We also have been] [added: By way of example, we were] adversely affected by the inability of our suppliers to deliver components [removed: or] [added: and] raw materials on a timely [removed: basis, as happened] [added: basis] in connection with the COVID-19 pandemic.

Further, [removed: while] we [removed: make efforts to diversify our suppliers, in many instances there may be a single source] [added: have multiple single-source] or [removed: sole supplier] [added: sole-source suppliers] with no alternatives yet identified.

Our dependence on such [removed: single] [added: single-] or sole-source suppliers subjects us to possible risks of shortages, interruptions, and price fluctuations.

The costs of certain raw materials, logistics, and services necessary for the production and distribution of our products [removed: continue] [added: are subject] to [removed: fluctuate] [added: fluctuation] based on many factors beyond our control, including but not limited to changes in general economic conditions, labor costs, transportation costs, and currency exchange rates.

The risks of disruption described above, as well as the risks arising from war, geopolitical conflicts, government sanctions or trade controls, imposition of tariffs, natural disasters, climate change-related physical and transitional risks, actual or threatened public health crises, epidemics, and pandemics, [added: cybersecurity incidents] or other [added: disruptions impacting information technology systems, or other] business continuity events, could adversely affect our operations and [added: our suppliers’ ability to deliver, and] limit our ability to meet our commitments to customers or significantly impact our financial results and condition.

These processes may result in increased dependency on external [removed: suppliers.][added: suppliers and other third parties.]

Additionally, the implementation of localization requirements and other government policies driven by support of local [removed: industry] [added: industry,] and increasing attention to ESG matters, including EH&S matters, may impose additional costs [added: and requirements] on our [removed: business and] [added: business, such as the need to qualify new local suppliers or comply with new material reporting requirements, which] could negatively affect our ability to compete in certain markets.

We are dependent on our global production and operating network to develop, manufacture, assemble, supply, [added: transport, ship, warehouse,] and service our offerings.

A work stoppage, labor shortage, or other production limitation, including import or export restrictions and transportation issues, among others, could occur at our [removed: manufacturing] [added: facilities,] facilities [added: of suppliers] or [removed: at supplier] [added: other third parties on which we rely,] or customer facilities, and [added: could] negatively impact our reputation and market position.

Any significant event affecting one of our [removed: or our suppliers’] production or operating facilities may result in a disruption to our ability to supply customers, and standby capacity necessary for the reliable operation of the facility may not be sufficiently available.

[removed: Any of these risks] [added: investigation, or complaint and any adverse publicity surrounding such allegations or actions] could have a material adverse effect on our business results, cash flows, financial condition, or prospects.

These net liabilities arise under multiple [added: retirement] benefit plans and statutory obligations in various countries.

We may not be successful in driving the global deployment and customer adoption of digital offerings characterized by digital applications and solutions.

- Developments following regulatory authorization, including results in post-approval device or pharmaceutical Phase 4 trials or other studies, could adversely affect sales or decrease demand for our medical devices or pharmaceutical products.

- Our certificate of incorporation provides that certain courts in the State of Delaware or the federal district courts of the United States will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

- Changes in foreign currency exchange rates, equity prices, and interest rates, and unfavorable changes in economic conditions or uncertainties that effect the capital markets could adversely affect our financial performance.

- Future material impairments in the value of our long-lived assets, including goodwill, could adversely affect our business.

- Certain of our directors and employees may have actual or potential conflicts of interest because of their financial interests in GE or because of their previous or continuing positions with GE.

- Certain provisions in our certificate of incorporation, bylaws, and Delaware law may discourage takeovers.

- We or GE may fail to perform under various transaction agreements executed as part of the Spin-Off.

INDUSTRY AND ECONOMIC RISKS.

Increased competition from ISOs and evolving regulatory and legislative policies could adversely impact our business and results of operations.

In addition to affecting our services business, the activities of ISOs could expose us to a number of other risks related to safety, quality, security, or performance of our products.

We expect the U.S. healthcare industry to continue to change in the future.

For example, in March 2024, the government in China announced a new stimulus program (“2024 stimulus”) that includes the healthcare sector and is being implemented through China’s provinces.

In addition, an anti-corruption campaign directed at the healthcare sector remains ongoing.

Both of these factors contributed to delayed orders and sales in our China business throughout 2024.

While we expect the 2024 stimulus program to result in opportunities for our business in China in the longer term, it has had a short-term impact as provinces develop and announce their plans and customers begin to make purchasing decisions.

We expect the effects of the delay in the 2024 stimulus and the anti-corruption campaign to continue to impact our orders and sales in the near term, although we are unable to predict the exact duration or magnitude of the impact.

For example, in late 2024 and early 2025, the United States, China, and the European Union each announced either new tariffs, non-tariff barriers (principally related to participation in public procurement of healthcare equipment), or export controls.

Under the current U.S. Department of Commerce regulations, we are permitted to export, re-export, or transfer medical equipment and spare parts that meet stated criteria under a License Exception, which has eliminated the need for us to obtain individual U.S. licenses in most cases; however, licenses still may be needed for some transactions.

We will continue to apply for licenses to supply to these customers and to support our business in Russia, as required.

BUSINESS AND OPERATIONAL RISKS.

As we seek to build clinical applications that leverage generative AI models built by third parties, we may have limited rights to access the underlying intellectual property used to create the generative AI model, and, if requested, this may limit or impair our ability to independently verify the explainability, transparency, and reliability of the underlying model.

Additionally, our obligations to comply with the evolving legal and regulatory landscape could entail significant costs or limit our ability to incorporate certain AI capabilities into our offerings.

We rely on third-party transport and warehouse management services for reliable and secure point-to-point transportation of our products to our customers and patients, tracking of these shipments, and warehousing of our products.

If any of these third parties were to encounter delivery performance issues or other disruptions leading to the loss, damage, or destruction of our products, it would be costly to replace these products in a timely manner.

This may damage our reputation and result in decreased demand for our products.

creating new attack methods for adversaries.

We also rely on agreements with certain employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights.

We cannot be certain that these agreements will not be breached, that such provisions will be enforceable, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information, or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge.

We face attention from investors, regulators, and other stakeholders, who may have conflicting views, related to our ESG positions, performance, and disclosures.

We are subject to legal and regulatory requirements that focus on our ESG positions, performance, and disclosures.

These requirements continue to broaden and may be conflicting, both in terms of scope and geography, a trend we expect to continue.

While these goals reflect our current plans and aspirations, we may need to adjust or revise them in light of changes to the assumptions made at the time they were set or the emergence of risks related to our ability to deliver them.

industry standards, or competitors’ innovations or reverse engineering efforts.

Changes to current products and labeling may also be subject to vigorous review, and approvals or the time needed to secure approvals are not certain.

We are subject to regulations requiring restrictions, certification, and/or licensing of our facilities, and our facilities are subject to periodic inspections by regulatory authorities.

Adverse inspection outcomes have in the past, and may in the future, impact our ability to develop, manufacture, market, or distribute certain products.

We also carefully monitor the quality and performance of our products once they are distributed.

We may identify problems with product design, manufacturing, labeling, distribution, or other issues that impact the safety, quality, or performance of our products.

These types of issues have in the past, and could in the future, create risk to patients, clinicians, or other personnel in contact with our products and lead to product recalls, removals, replacement, servicing, or other corrective actions.

- Our business dealings involve third-party partners in various markets, and the actions or inactions of these third parties could adversely affect our business.

- Our inability to successfully complete strategic transactions could adversely affect our business.

- We rely on third parties to help perform logistics, transportation, shipping, warehousing, and services functions on our behalf, and disruptions at these third-party providers could adversely affect our business.

- Public health crises, epidemics, and pandemics, such as the COVID-19 pandemic, have had and in the future may have a material adverse impact on our business, as well as on the operations and financial performance of some of the customers and suppliers in industries that we serve.

- We may be unable to obtain, maintain, protect, or effectively enforce our IP rights.

- Failure to comply with the FCPA and similar anti-corruption and anti-bribery laws globally has resulted and could continue to result in civil or criminal sanctions and adversely affect our business.

- We are subject to antitrust and competition laws that can result in sanctions and conditions on the way we conduct our business.

- We may become involved in litigation, arbitration, and governmental proceedings, including those stemming from third-party conduct beyond our control.

- Substantial sales of our common stock, including the disposition by GE of our shares of common stock that it retained after our Spin-Off, could cause our stock price to decline or be volatile.

RISKS RELATED TO OUR BUSINESS AND OUR INDUSTRY.

*Risks Relating to Our Operations*

Increased competition from ISOs (“third-party” entities that specialize in the repair and maintenance of medical devices produced by OEMs, including us) and evolving regulatory and legislative policies could adversely impact our business and results of operations by driving down quality and price levels for services and repairs.

Our business dealings involve third-party partners in various markets, and the actions or inactions of these third parties could adversely affect our business.

Any interruption in the operations of our manufacturing facilities, or our suppliers’ or customers’ facilities, may impair our ability to deliver products or provide services.

We rely on third parties to help perform logistics, transportation, shipping, warehousing, and services functions on our behalf, and disruptions at these third-party providers could adversely affect our business.

Third-party providers help perform our logistics, transportation, shipping, warehousing, and services functions.

If any of these providers fails to honor a contractual relationship with us, suffers a business interruption, or experiences delays, disruptions, or quality control problems in its operations, including due to pandemics, regional conflicts, sanctions, geopolitical events, natural disasters, or extreme weather events, or if we have to change and qualify alternative providers for these services, shipments to our customers may be delayed.

Increased costs and delays, including as a result of labor shortages, disruptions in transportation lines, international air freight capacity limitations, driver and truck capacity limitations, airport and port congestion, and delays in customs processes, could have a material adverse effect on our business results, cash flows, financial condition, or prospects.

While the increased availability of flexible, hybrid, or work-from-home arrangements has afforded us the ability to attract and retain talent from geographies remote from our physical offices, it has also expanded competition by allowing qualified employees within those same regions to pursue job opportunities throughout the country without the need to relocate.

In the past, the COVID-19 pandemic affected economic activity globally or in various regions, and in the future, the COVID-19 pandemic, or another public health crisis, epidemic, or pandemic, could adversely impact our future operations and financial performance.

*Risks Relating to Technology and Intellectual Property*

We are subject to stringent privacy laws and information security policies and regulations.

Moreover, our digital ecosystem, which is intended to provide our customers with greater access to a broad array of personal and sensitive information to improve delivery of care to their patients, heightens our risks associated with the protection of such information.

There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information.

In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of PHI, require the implementation of safeguards to protect the privacy and security of PHI and ensure the confidentiality, integrity, and availability of electronic PHI, and require the provision of notice in the event of a breach of PHI.

If we are unable to properly protect the privacy and security of PHI, we could face liability for breach of our contracts with our customers.

Further, if we fail to comply with applicable HIPAA privacy and security standards, we could face civil and criminal penalties.

In addition, there are also various state-level laws (e.g., the California Consumer Privacy Act), both enacted and proposed, that we must monitor for applicability and impact to our business and for which we must implement necessary controls and other requirements (if applicable).

In addition, we are subject to the laws and regulations of foreign jurisdictions including, without limitation, the GDPR in the EU and the United Kingdom (“U.K.”) data protection legislation (including the GDPR, as it forms part of the law of the U.K. by virtue of the U.K. GDPR and the U.K. Data Protection Act 2018 (the “U.K. Data Protection Act”)).

The GDPR contains robust, direct obligations on data processors in addition to data controllers, heavier documentation requirements for company data protection compliance programs, stringent reporting obligations of data breach to data protection authorities, and a prohibition on the transfer of personal data from the EU to other countries whose laws do not protect personal data to an adequate level of privacy or security (unless an approved cross-border transfer mechanism, such as binding corporate rules for personal data transfers, is maintained).

Data protection authorities have the power to impose substantial administrative fines for violations of the GDPR and the U.K. GDPR.

Such penalties are in addition to any civil litigation or damages from claims by data controllers, customers, and data subjects.

If we fail to comply with the GDPR, the U.K. GDPR, and the U.K. Data Protection Act, we could face fines, penalties, and harm to our reputation.

In China, we are subject to laws and regulations governing both the use and disclosure of confidential patient medical information that may become more restrictive in the future, including restrictions on transfer of healthcare data (e.g., China PIPL).

In China, we are also subject to the Cyber Security Law of China and accompanying regulations, which designate healthcare as a priority area that is part of critical information infrastructure and has recently increased privacy protections.

Some of our products may be required to comply with detailed standards or guidance documents on cybersecurity and privacy issued by various regulatory authorities.

Should the privacy or cybersecurity regime in China become more stringent, we could be required to implement additional safeguards and systems, which could be costly and cause disruption to our business in China.

In addition, privacy laws and regulations in other regions of the world, such as Asia and Latin America, are becoming stricter and may potentially impose additional requirements on our business (e.g., Brazil’s General Data Protection Law (Lei Geral de Proteção de Dados Pessoias)), and certain jurisdictions have implemented data localization laws that can be costly and operationally difficult to satisfy.

The costs associated with the investigation, remediation, and potential notification of any violation to customers, regulators, and counterparties could be material.

We are subject to anti-kickback and false claims laws and failure to comply with these laws could adversely affect our business.

| [Trends and Factors Impacting Our [removed: Performance](#i221eafb883df4809b0de60c20b424759_115)] [added: Performance](#ic5f48a2b80264b159361fdd8ef5e37cf_106)] | | | [removed: [48](#i221eafb883df4809b0de60c20b424759_115)] [added: [39](#ic5f48a2b80264b159361fdd8ef5e37cf_106)] | | |

| [Summary of Key Performance [removed: Measures](#i221eafb883df4809b0de60c20b424759_118)] [added: Measures](#ic5f48a2b80264b159361fdd8ef5e37cf_109)] | | | [removed: [49](#i221eafb883df4809b0de60c20b424759_118)] [added: [40](#ic5f48a2b80264b159361fdd8ef5e37cf_109)] | | |

| [Results of [removed: Operations](#i221eafb883df4809b0de60c20b424759_124)] [added: Operations] – [removed: [Segments](#i221eafb883df4809b0de60c20b424759_124)] [added: Segments](#ic5f48a2b80264b159361fdd8ef5e37cf_115)] | | | [removed: [53](#i221eafb883df4809b0de60c20b424759_124)] [added: [44](#ic5f48a2b80264b159361fdd8ef5e37cf_115)] | | |

| [Non-GAAP Financial [removed: Measures](#i221eafb883df4809b0de60c20b424759_127)] [added: Measures](#ic5f48a2b80264b159361fdd8ef5e37cf_118)] | | | [removed: [54](#i221eafb883df4809b0de60c20b424759_127)] [added: [45](#ic5f48a2b80264b159361fdd8ef5e37cf_118)] | | |

| [Liquidity and Capital [removed: Resources](#i221eafb883df4809b0de60c20b424759_130)] [added: Resources](#ic5f48a2b80264b159361fdd8ef5e37cf_121)] | | | [removed: [58](#i221eafb883df4809b0de60c20b424759_130)] [added: [50](#ic5f48a2b80264b159361fdd8ef5e37cf_121)] | | |

| [Recently Issued Accounting [removed: Pronouncements](#i221eafb883df4809b0de60c20b424759_133)] [added: Pronouncements](#ic5f48a2b80264b159361fdd8ef5e37cf_124)] | | | [removed: [59](#i221eafb883df4809b0de60c20b424759_133)] [added: [52](#ic5f48a2b80264b159361fdd8ef5e37cf_124)] | | |

| [Critical Accounting [removed: Estimates](#i221eafb883df4809b0de60c20b424759_211)] [added: Estimates](#ic5f48a2b80264b159361fdd8ef5e37cf_127)] | | | [removed: [59](#i221eafb883df4809b0de60c20b424759_211)] [added: [52](#ic5f48a2b80264b159361fdd8ef5e37cf_127)] | | |

The following discussion and analysis of our financial [removed: condition and] results [removed: of operations] should be read in conjunction with the consolidated and combined financial statements and corresponding notes [added: (the “financial statements”)] included elsewhere in this Annual Report on Form 10-K.

The following discussion and analysis provide information management believes to be relevant to understanding the financial [removed: condition and] results of [removed: operations of] GE HealthCare Technologies Inc. [added: and its subsidiaries] (“GE HealthCare,” the “Company,” “our,” [added: “us,”] or “we”) for the years ended December 31, [removed: 2023] [added: 2024, 2023,] and 2022.

[added: This discussion contains forward-looking statements that are based upon current expectations and are subject to uncertainty and changes in circumstances; see “Forward-Looking Statements.”] Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed below and elsewhere in this Annual Report on Form 10-K, and particularly in Item [removed: 1A.][added: 1A, “Risk Factors.”]

For additional information on the nature of our business [removed: see] [added: and our segments, refer to] Item [removed: 1.][added: 1, “Business” and Note 4, “Segment and Geographical Information.”]

We believe that our performance and future success depend on a number of factors that present significant opportunities for us but also pose risks and challenges, including those discussed below and particularly in Item [removed: 1A.][added: 1A, “Risk Factors.”]

We had [removed: $153] [added: $162] million and [removed: $143] [added: $153] million of assets in, or directly related to, Russia and Ukraine as of December 31, [removed: 2023] [added: 2024] and December 31, [removed: 2022,] [added: 2023,] respectively, none of which are subject to sanctions that impact the carrying value of the assets.

We generated revenues of [added: $363 million,] $340 [removed: million] [added: million,] and $395 million from customers in these two countries for the years ended December 31, [removed: 2023] [added: 2024, 2023,] and [removed: December 31,] 2022, respectively.

The European Union and other countries have also expanded licensing requirements for certain spare [removed: parts] [added: parts, services, software,] and other items.

The implementation of these measures affected our ability to supply customers in Russia during the [removed: last three quarters of] [added: years ended December 31, 2024 and] 2023 and will continue to do so as we [added: confirm applicability of the U.S. License Exception to our transactions and] continue to obtain licenses.

[removed: Revenues] [added: Financial results] in the fourth quarter have historically been higher than in other quarters due to the spending patterns of our customers.

For additional information, see Note 1, “Organization and Basis of [removed: Presentation” to the consolidated and combined financial statements.][added: Presentation.”]

As a result of the Spin-Off, we are subject to [removed: the requirements of the] federal and state securities laws and stock exchange requirements.

The value of the assets and liabilities as of December 31, [removed: 2023, including the plans sponsored by GE HealthCare prior to the Spin-Off,] [added: 2024,] are [removed: shown] [added: summarized] in the table below.

[removed: As a result of the liabilities and assets transferred to GE HealthCare on January 1, 2023, we] [added: We] disclose in the following table postretirement plans with assets or obligations that exceed $50 million as of December 31, [removed: 2023.][added: 2024.]

Refer to Note 10, “Postretirement Benefit Plans” [removed: to the consolidated and combined financial statements] for further details related to these plans.

| GE HealthCare Supplementary Pension Plan | | | [removed: 2,022] [added: 1,886] | | | — | | | [removed: (2,022)] [added: (1,886)] | | |

| OPEB Plans(1) | | | [removed: 1,133] [added: 1,016] | | | — | | | [removed: (1,133)] [added: (1,016)] | | |

We have [removed: and expect to continue to institute] [added: instituted] competitive compensation policies and programs as an independent public company.

The expense for these policies and programs [removed: will increase] [added: increased] from the compensation expense allocated by GE in years prior to the Spin-Off, driven primarily by higher cash and stock compensation to retain employees and align more closely with industry peers.

Management reviews and analyzes several key performance measures including Total revenues, [removed: Remaining Performance Obligations (“RPO”),] Operating income, Net income attributable to GE HealthCare, Earnings per [removed: share – continuing operations,] [added: share,] and Cash from (used for) operating [removed: activities – continuing operations.][added: activities.]

| Consolidated and Combined Statements of Income | | | | | | | | | [added: For the years ended December 31] | | | | | | | | | [added: | | |]

| | | | | | | | | | For the years ended December 31 | | | | | | | | | [added: | | | | | | | | | | | | | | | | | | | | | | | | | | |]

| | | | | | | | | | | | | [added: 2024 | | |] 2023 | | | 2022 | | |

| Sales of products | | | | | | | | | | | | $ | [added: 13,075 | | $ |] 13,127 | | $ | 12,044 | |

| Sales of services | | | | | | | | | | | | [added: 6,597 | | |] 6,425 | | | 6,297 | | |

| Total revenues | | | [removed: | | | | | | | |] [added: $] | 19,552 | | [added: $] | 18,341 | | [added: 7%] | [added: | |]

| Cost of products | | | | | | | | | | | | [added: 8,271 | | |] 8,465 | | | 7,975 | | |

| Cost of services | | | | | | | | | | | | [added: 3,196 | | |] 3,165 | | | 3,187 | | |

| Gross profit | | | | | | | | | | | | [added: 8,205 | | |] 7,922 | | | 7,179 | | |

| Selling, general, and administrative | | | | | | | | | | | | [added: 4,269 | | |] 4,282 | | | 3,631 | | |

| Research and development | | | | | | | | | | | | [added: 1,311 | | |] 1,205 | | | 1,026 | | |

| Total operating expenses | | | | | | | | | | | | [added: 5,580 | | |] 5,487 | | | 4,657 | | |

| Operating income | | | | | | | | | | | | [added: 2,625 | | |] 2,435 | | | 2,522 | | |

| [Results of Operations](#ic5f48a2b80264b159361fdd8ef5e37cf_112) | | | [41](#ic5f48a2b80264b159361fdd8ef5e37cf_112) | | |

On January 3, 2023, the General Electric Company, which now operates as GE Aerospace (“GE”), completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”).

For further information regarding the Spin-Off, refer to Note 1, “Organization and Basis of Presentation.”

Certain columns and rows may not sum due to the use of rounded numbers.

Percentages presented are calculated from the underlying whole-dollar amounts, and unless otherwise stated, represent changes year-over-year.

Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting.

The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”).

Following this realignment, the Company continues to have four reportable segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”).

These segments have been identified based on the nature of the products sold and how the Company manages its operations.

Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure.

Under the current U.S. Department of Commerce regulations, we are permitted to export, re-export, or transfer medical equipment and spare parts that meet stated criteria under a License Exception, which has eliminated the need for us to obtain individual U.S. licenses in most cases; however, licenses still may be needed for some transactions.

We will continue to apply for licenses to supply to these customers and to support our business in Russia, as required.

*China Market*

We continue to monitor developments in the market in China.

In March 2024, the government in China announced a new stimulus program (“2024 stimulus”) that includes the healthcare sector and is being implemented through China’s provinces.

In addition, an anti-corruption campaign directed at the healthcare sector remains ongoing.

Both of these factors contributed to delayed orders and sales in our China business throughout 2024.

We expect the 2024 stimulus program will result in opportunities for our business in China in the longer term, but it has had a short-term impact as provinces develop and announce their plans and customers begin to make purchasing decisions.

We expect the effects of the delay in the 2024 stimulus and the anti-corruption campaign to continue to impact our orders and sales in the near term, although we are unable to predict the exact duration or magnitude of the impact.

We expect both of these impacts to be temporary, and we believe the focus of government policy in China on expanding access to healthcare will benefit our business in China in the long term.

*Tariffs*

In February 2025, the United States imposed additional tariffs on products from China.

These tariffs, and any future tariffs, including on products from Mexico or Canada, by the United States or other countries, will likely result in additional costs to us.

The impact of tariffs will depend on various factors including the timing, amount, scope, and nature of the tariffs, and any mitigating actions we implement.

*Tax Valuation Allowances*

Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years.

We evaluate the recoverability of these future tax deductions and credits by evaluating all available positive and negative evidence.

We have a valuation allowance against certain U.S. and foreign deferred tax assets and will release the valuation allowance when there is sufficient positive evidence to support a conclusion that it is more likely than not the deferred tax assets will be realized.

For additional information regarding our income taxes, see Note 11, “Income Taxes.”

| | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | |

TOTAL REVENUES.

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | 2024 | | | 2023 | | | 2022 | | | 2024 vs. 2023 % change | | | 2023 vs. 2022 % change | | | 2024 vs. 2023 % organic* change | | | 2023 vs. 2022 % organic* change | | |

| Imaging | | | | | | | | | | | | | | | | | | $ | 8,855 | | $ | 8,944 | | $ | 8,395 | | (1)% | | | 7% | | | (1)% | | | 8% | | |

| [Results of Operations](#i221eafb883df4809b0de60c20b424759_121) | | | [50](#i221eafb883df4809b0de60c20b424759_121) | | |

For additional information on the year ended December 31, 2021 and year-over-year comparisons to December 31, 2022, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

This discussion contains forward-looking statements that are based upon current expectations and are subject to uncertainty and changes in circumstances.

“Risk Factors”.

Actual results may differ materially from these expectations; see “Forward-Looking Statements.”

Unless the context otherwise requires, references to “GE HealthCare,” “we,” “us,” “our,” and the “Company” refer to (1) General Electric Company’s (“GE’s”) healthcare business prior to the previously announced spin-off of the Company on January 3, 2023 (the “Spin-Off”) as a carve-out business of GE with related combined financial statements and (2) GE HealthCare Technologies Inc. and its subsidiaries following the Spin-Off with related consolidated financial statements.

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”) and we evaluate their operating performance using revenue and Segment EBIT.

“Business.”

“Risk Factors.”

*Manufacturing, Sourcing, and Supply Chain Management*

Our suppliers must provide us with quality products in substantial quantities, in compliance with regulatory requirements, at acceptable costs and on a timely basis.

Trends affecting the supply chain for the previous two years include the impact of increasing prices of labor and raw materials, limitations on capacity, and increased cost of shipping.

While we have seen some easing of these pressures in 2023, continued cost inflation or the return of material scarcity in our supply chain could have adverse impacts on our future results.

In May 2023, the U.S. Department of Commerce implemented expanded measures that require us to obtain a license for the export, re-export, or transfer of specified medical equipment and spare parts to customers in Russia.

We have successfully applied and continue to apply for the licenses required to supply to these customers.

In addition, cash from operating activities is typically higher in the fourth quarter sequentially as inventories are lower as a result of higher revenues.

*Pension and Other Benefit-Related Liabilities*

In connection with the Spin-Off, on January 1, 2023, GE HealthCare assumed a net postretirement benefit obligation of $4,045 million, in addition to the existing GE HealthCare net postretirement benefit obligation of $278 million, for a total net obligation of $4,323 million.

| GE HealthCare Pension Plan | | | $ | 16,138 | | $ | 14,700 | | $ | (1,438) | |

| Total Principal Pension Plans | | | 18,160 | | | 14,700 | | | (3,460) | | |

| Other Pension Plans(1) | | | 4,588 | | | 4,518 | | | (70) | | |

| Total | | | $ | 23,881 | | $ | 19,218 | | $ | (4,663) | |

| (1) As defined in Note 10, “Postretirement Benefit Plans” to our consolidated and combined financial statements. | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

TOTAL REVENUES AND RPO.

| Imaging | | | | | | | | | | | | | | | | | | $ | 10,581 | | $ | 9,985 | | 6% | | | 7% | | |

| Ultrasound | | | | | | | | | | | | | | | | | | 3,457 | | | 3,422 | | | 1% | | | 2% | | |

| | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Revenues by Region | | | | | | | | | | | | | | | | | | | | | | | |

| Remaining Performance Obligations | | | | | | | | | | | | | | | | | |

| | | | As of | | | | | | | | | | | | | | |

| Products | | | $ | 4,930 | | $ | 4,992 | | | | | (1)% | | | | | |

| Services | | | 9,725 | | | 9,351 | | | | | | 4% | | | | | |

| Total RPO | | | $ | 14,655 | | $ | 14,343 | | | | | 2% | | | | | |

RPO represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty.

RPO as of December 31, 2023 increased 2% from December 31, 2022, primarily due to new and renewals of multi-year service contracts in USCAN and EMEA.

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

We are exposed to market risk primarily from changes in [removed: interest rates,] foreign currency exchange rates, [added: interest rates,] commodity prices, and equity prices, which may impact future income, cash flows, and fair value of our business.

In certain situations, we may seek to reduce cash flow volatility associated with changes in foreign currency exchange rates, the foreign currency risk associated with our net investment in foreign operations, or the fair value interest rate risk of our financial instruments bearing fixed interest by entering into financial arrangements intended to provide a hedge against a portion of [removed: the risks associated with] such risks.

We use a number of techniques to manage the effects of [added: foreign] currency [removed: exchange,] [added: exchange risk,] including hedging of significant currency exposures.

We use cash flow hedging primarily to reduce or eliminate the effects of foreign currency exchange rate changes on purchase and sale contracts and economic hedges when we have exposures to [added: foreign] currency exchange risk for which we are unable to meet the requirements for hedge accounting.

The potential decrease in fair value of our foreign currency derivative contracts from a 10% decrease in USD spot rates against other applicable currencies would have been [removed: $13] [added: $82] million as of December 31, [removed: 2023.][added: 2024.]

The sensitivity analysis assumes a uniform weakening of USD spot rates against the other applicable currencies, compared to the actual exchange rates applied as of December 31, [removed: 2023,] [added: 2024,] with all other factors remaining constant.

See Note 2, “Summary of Significant Accounting Policies” for net gains (losses) from foreign currency transactions for the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021.][added: 2022.]

We are exposed to interest rate risk due to changes in benchmark interest [removed: rates,] [added: rates] related to the fair value of our borrowings bearing fixed interest rates and variability of cash flows related to our investments and borrowings bearing variable interest rates.

As of December 31, [removed: 2023,] [added: 2024,] we have $8,250 million of fixed-rate debt and [removed: $1,150] [added: $750] million outstanding on the Term Loan Facility which carries a variable interest rate.

As of December 31, [removed: 2023,] [added: 2024,] we have [removed: $2,504] [added: $2,889] million of Cash, cash equivalents, and restricted cash, [added: of] which [removed: are] [added: $1,885 million is] invested in short-term investments that generate income based on variable interest rates.

A hypothetical change of interest rates by 100 basis points would increase or decrease our annual interest expense by approximately [removed: $22] [added: $35] million, partially offset by the change in interest income from our cash investments.

[removed: We entered into interest-rate] [added: As of December 31, 2024, we executed an aggregate notional amount of interest rate] swap contracts [removed: in the fourth quarter of 2023,] to synthetically convert [removed: $1,000] [added: $2,700] million of our senior unsecured notes from fixed rates to variable rates as part of our interest rate risk management strategy.

As of December 31, [removed: 2023,] [added: 2024,] we have [removed: $269] [added: $260] million of deferred compensation liabilities subject to the risk of changes in equity prices.

A change in the U.S equity markets would result in a corresponding change in the [removed: fair] value of these deferred compensation liabilities, which would impact our earnings and cash flows.

See Note 13, “Financial Instruments and Fair Value Measurements” [removed: to the consolidated and combined financial statements] for further information about our risk exposures, our use of derivatives, and the effects of this activity on our [removed: consolidated and combined] financial statements.

GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” or “we”) is a [added: trusted partner and] leading global [added: healthcare solutions provider, innovating] medical technology, pharmaceutical diagnostics, and [removed: digital solutions innovator.][added: integrated, cloud-first AI-enabled solutions, services, and data analytics.]

We have approximately [removed: 51,000] [added: 53,000] colleagues dedicated to our mission to create a world where healthcare has no limits.

Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from [added: screening and] diagnosis to therapy [removed: to] [added: and] monitoring.

Precision care is expected to drive continued demand and the need for novel technologies and future innovation, as healthcare providers and researchers seek new solutions and tools for managing [removed: existing and new care pathways.][added: various disease states.]

The pursuit of precision care opportunities significantly expands our addressable [removed: industries] [added: markets] to include integrated diagnostics, AI and machine learning-based clinical decision support, highly personalized therapies enabled by more precise diagnostics, and remote patient monitoring.

We serve customers in [removed: approximately] [added: over] 160 countries with a global team of [removed: 9,900] [added: approximately 9,800] sales [removed: professionals, 8,100] [added: professionals and 8,300] field service [removed: engineers, and a network of 43 manufacturing, assembly, and pharmaceutical production sites across 17 countries.][added: engineers.]

We are organized into four business segments that are aligned with the industries we serve: Imaging, [removed: Ultrasound,] [added: Advanced Visualization Solutions (“AVS”),] Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”).

Our portfolio of solutions addresses the biggest challenges facing healthcare providers and patients today, [removed: including helping to] [added: and helps] drive better patient outcomes and improved productivity for customers.

These qualities foster [removed: strong] trust, loyalty, and partnership with our global customer base.

On January 3, 2023, the General Electric [removed: Company (“GE”)] [added: Company, which now operates as GE Aerospace (“GE”),] completed the [removed: previously announced] spin-off of GE HealthCare (the “Spin-Off”).

Our Imaging portfolio spans the care continuum and provides critical tools for [removed: physicians,] [added: clinicians,] from initial screening and diagnosis, through therapeutic decision-making and monitoring of patient progression.

Our Imaging portfolio [removed: is comprised of six] [added: includes five] product lines and associated service capabilities: Molecular [removed: Imaging,] [added: Imaging (“MI”),] Computed [removed: Tomography,] [added: Tomography (“CT”),] Magnetic [removed: Resonance, Image-Guided Therapies,] [added: Resonance (“MR”),] Women’s Health, and X-ray.

- Molecular imaging [removed: (“MI”)] enables the visualization, characterization, and quantification of functional processes taking place at the cellular and subcellular levels within patients.

We offer a complete MI solution from cyclotrons, chemistry synthesis, positron emission tomography (“PET”), computed tomography (“PET/CT”), PET/MR, and nuclear medicine to advanced digital [added: and AI-enabled] solutions.

- Computed tomography [removed: (“CT”)] scans render 3D anatomical images of structures, such as bone, soft tissue, and air cavities using an X-ray tube that rotates around a patient.

- Magnetic resonance [removed: (“MR”)] is a non-invasive imaging technology that produces detailed anatomical images of almost every internal structure in the human body, such as the brain, spinal cord, heart, breast, kidneys, muscles, ligaments, and tendons.

We also offer a suite of [added: AI-enabled] software and applications that help [removed: radiology teams] [added: clinicians] improve productivity, address staff shortages, and deliver better patient outcomes.

We also offer Picture Archiving and Communication Systems [added: (“PACS”)] and Radiological Information Systems to manage the storage and reporting of radiology images.

GE HealthCare is a global leader in [removed: ultrasound medical devices] [added: ultrasound, image guided therapies,] and [added: interventional] solutions with a broad portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases.

Our [removed: Ultrasound business’ focus] [added: AVS business] is [added: focused] on designing solutions that are aligned by specialties or care areas for specific clinical workflows to better serve the unique needs of our customers and improve patient [removed: outcomes, while lowering the overall cost of care.][added: outcomes.]

We continue to deliver innovative [removed: ultrasound probes, consoles, and] [added: solutions to support interventional procedures, all with] digital and [removed: AI] [added: AI-enabled] solutions that [added: help clinicians] increase diagnostic [removed: accuracy and simplify] [added: confidence, while simplifying] clinical and operational workflows.

- [removed: Radiology and Primary] [added: Comprehensive] Care Ultrasound [removed: is comprised of] [added: includes] systems that produce images to support precise [removed: diagnoses] [added: screening, diagnosis, monitoring,] and treatment across the whole body, including liver, thyroid, [removed: renal,] [added: kidney,] breast, vascular, and transcranial applications.

Our systems combine high image quality with comprehensive clinical [removed: tools,] [added: tools] including measurement quantification, workflow automation, cross-modality networking, [removed: portability,] [added: real-time] and [added: AI-enabled scan guidance, and] cloud-based [removed: technologies.][added: technologies with versatility, accessibility, and portability required to deliver care.]

- Women’s Health Ultrasound [removed: is comprised of] [added: provides systems to support] obstetrics, gynecology, [added: and] assisted reproductive [removed: medicine, and supplemental breast cancer screening.][added: medicine.]

These care areas require [removed: specially-designed] [added: specially designed] ultrasound products that account for patient comfort and workflow constraints to enable practitioners to provide higher-quality screening, exams, and procedural [removed: care.][added: care, and give clinicians images with the clarity and definition they need to focus on early detection and intervention.]

Each clinical area is supported with our digital and [removed: AI Ultrasound] [added: AI-enabled ultrasound] solutions that are designed to deliver optimal, simplified, and scalable clinical and operational workflows.

They are designed to increase efficiencies that support [removed: higher scan volume and billing opportunities] [added: care for more patients] by: providing AI-guided ultrasound to help [removed: experienced to novice] clinicians [added: of all experience levels] acquire quality diagnostic images; eliminating keystrokes to shorten exam time; and providing clinical decision support tools.

Clinicians are further supported by our broad probe portfolio which includes specialized probes for [removed: surgical intervention and transesophageal] [added: interventional] procedures.

[removed: The Patient Care Solutions business] [added: GE HealthCare’s PCS segment] is a leading global provider of medical devices, [added: proprietary parameters and] consumables, services, and digital solutions that acquire and transform complex clinical data into real-time visualization and clinical decision support to ease the way to more confident patient care and improve patient outcomes.

[removed: Our devices, digital solutions, and service] [added: These] solutions form a broad and integrated portfolio that support patient care needs and care teams within and beyond most acute healthcare environments.

[removed: Our portfolio is comprised of] [added: Monitoring Solutions includes] Patient Monitoring, [removed: Anesthesia Delivery and Respiratory Care,] Diagnostic Cardiology, [removed: Maternal Infant Care, and] Consumables and Services [removed: connected by] [added: portfolio,] and [removed: differentiated with our digital solutions.][added: Digital Solutions.]

- Our flexible Patient Monitoring solutions enable clinicians to flex care based on a patient’s acuity and across [removed: all] the [removed: acute] care continuum.

Our Patient Monitoring business includes proprietary parameters and complementary consumables as well as original equipment [removed: manufacturer (“OEM”)] [added: manufacturers’] parameters that are integrated into our monitoring fleet, of which a significant portion represents recurring revenue streams.

[removed: Products in our] [added: -] Anesthesia [removed: portfolio] [added: products offer life support solutions via ventilation technology and] are used by anesthesiologists and nurse anesthetists to ventilate and deliver general anesthetic drugs to patients during surgeries.

Our products are installed in many operating rooms, non-operating room anesthesia [removed: environments] [added: environments,] and ambulatory surgical centers across the world.

- In Diagnostic Cardiology, we offer electrocardiogram (“ECG” or “EKG”) solutions, that are usually the first diagnostic tool to detect cardiovascular disease, a leading cause of death [removed: across the world.][added: globally.]

Our ECG ecosystem obtains, interprets, and stores ECGs captured from devices in both hospital and home settings, supporting patients and clinicians along the continuum of [removed: care for cardiology.][added: cardiology care.]

- Our Consumables and Services portfolio consists of approximately 1,000 consumables that are used [added: throughout the hospital] primarily with our [removed: monitoring solutions patient parameters,] [added: monitors and therapy devices,] such as blood pressure, ECG, [removed: pulse,] [added: pulse oximetry,] temperature, respiratory rate, blood oxygen level, and brain [removed: activity, and are used throughout the hospital.][added: activity.]

[added: -] The Patient Care Solutions portfolio also includes digital solutions that provide [removed: timely and accurate] clinical decision support in acute and other care settings, simplifying clinical and operational workflows to drive efficiencies and [removed: improving] [added: helping improve] delivery of precision medicine and patient outcomes.

These solutions aggregate and integrate clinical data from various devices across care settings in real time and simplify visualization to guide clinical and operational decisions, enabling [added: more] efficient care team collaboration, virtually.

Our revenues and operating profits vary from quarter to quarter.

Financial results in the fourth quarter have historically been higher than in other quarters due to the spending patterns of our customers.

Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting.

The Ultrasound segment was subsequently renamed Advanced Visualization Solutions.

Following this realignment, the Company continues to have four reportable segments: Imaging, AVS, PCS, and PDx, as described below.

ADVANCED VISUALIZATION SOLUTIONS.

The AVS segment has a portfolio that serves customers across two core areas: Specialized Ultrasound and Procedural Guidance.

Specialized Ultrasound includes Comprehensive Care Ultrasound, and Women’s Health Ultrasound.

Procedural Guidance includes CardioVascular and Interventional Solutions, and Surgical Innovations.

These systems include point of care and handheld ultrasound devices to support clinical decision-making throughout various care pathways in diverse sites of care.

- CardioVascular and Interventional Solutions provides clinicians with tools to diagnose, treat, and monitor cardiovascular conditions with precision and confidence as well as technologies to help assist clinicians and surgeons during open surgeries and minimally invasive and interventional procedures.

This includes ultrasound systems used to assess the structure and function of the heart, as well as real-time advanced X-ray imaging that integrates with ultrasound and other imaging and diagnostic systems.

These technologies support planning, guiding, and assessing a variety of surgical procedures like cardiac interventions and those that involve insertion of devices like deep brain stimulators, spinal implants, and other neurological devices.

- Surgical Innovations products are used in the operating environment and include a broad portfolio of advanced mobile surgical C-arms that meet clinical needs for surgical imaging and are designed to be easily maneuverable in crowded operating rooms and adaptable for various surgical procedures.

Surgical visualization and guidance technology expands the use of ultrasound beyond diagnostics to provide real-time information during surgical procedures to help guide interventions and navigate inside the human body.

Our PCS portfolio serves care teams and healthcare systems across multiple patient care needs including Monitoring Solutions and Life Support Solutions.

Life Support Solutions includes Maternal Infant Care and Anesthesia.

Our unique combination of imaging equipment and pharmaceutical diagnostics enables building capabilities across disease states through diagnostic pharmaceuticals, hardware, software, and AI and digital solutions.

We deliver value through innovative medical technology solutions across the patient care continuum (including screening, diagnosis, and therapy, monitoring) by leveraging hardware, software, AI, and digital technologies.

We also both compete and partner with various digital health and healthcare AI participants.

We have objective measures in place to gauge the progress of our culture.

- Winning with an inclusive team.

This starts with attracting qualified candidates to the organization with a strong company value proposition and competitive total rewards.

A key pillar of our talent strategy is having senior management-led talent processes that yield succession readiness, strong leaders, and a more engaged, productive, and retained workforce.

We have approximately 900 union-represented manufacturing colleagues in the United States.

SUSTAINABILITY

- Promoting a culture of belonging for all;

Our supply chain design drives resilience and redundancy, including maintaining buffer capacity, diversifying our sourcing and manufacturing bases, and utilizing advanced risk-focused analytics.

REGULATION OF MEDICAL DEVICES AND PHARMACEUTICAL PRODUCTS.

The Food and Drug Administration (“FDA”) in the United States, the European Medicines Agency (“EMA”) (for pharmaceuticals) and European National Competent Authorities and Notified Bodies (for devices) in Europe, the National Medical Products Administration (“NMPA”) in China and other government agencies, such as state and local authorities, in the United States, Europe, and China, administer strict requirements governing the design, development, testing, performance, safety, quality, manufacturing, packaging, labeling, distribution, import/export, sale, servicing, marketing, and post-market surveillance of medical products, including medical devices and pharmaceutical products.

This requires, among other things, compliance with laws and regulations related to developing, testing, conducting clinical trials if needed, and receiving appropriate marketing authorization from the appropriate regulatory authorities prior to commercialization of our products where necessary.

We are also subject to extensive laws and regulations requiring ongoing compliance and monitoring of our products throughout the product lifecycle.

For example, we have extensive processes and procedures for monitoring the post-market safety and performance of our products, reporting applicable events to regulators, and taking action to address potential safety or quality concerns where needed.

In addition, regulators across the globe have the authority to conduct periodic inspections of our facilities, products, and Quality Management System processes and procedures to evaluate our compliance with applicable laws and regulations.

Regulators also monitor our advertising and promotion of products for compliance with applicable laws and regulations.

An enforcement or adverse action by a regulator could limit our ability to obtain regulatory authorizations or impact our ability to develop, market, distribute, or otherwise make our products available, depending on the nature of the action.

Additionally, in recent years, the EU has introduced upcoming legislation that would regulate the use and transfer of non-personal, technical data only.

Similar laws exist in some U.S. states as well.

Countries outside the United States have enacted similar local laws requiring medical device companies to report transfers of value to healthcare providers licensed in those countries.

| | | | | | | | | |

GE HealthCare has extensive reach throughout the global healthcare system for medical technology, pharmaceutical diagnostics, and digital solutions, underpinned by resilient, sustainable practices and products, and a commitment to growing access to care.

Our business is comprised of four segments:

- Our Image-Guided Therapies business provides technologies that assist clinicians and surgeons during open surgeries and minimally-invasive endovascular procedures.

Intraoperative imaging systems are used to visualize procedures that involve implants and devices, such as stents, balloons, pacemakers, and artificial joints.

Our Image-Guided Therapies business includes two business lines: interventional systems and surgery systems.

Our interventional systems are comprised of a broad portfolio of products that provide real-time advanced X-ray imaging and integrate with other imaging and diagnostic technologies that support clinicians in planning, guiding, and assessing minimally-invasive procedures.

Our surgical systems are comprised of a broad portfolio of mobile surgical C-arms that meet the varying clinical and environmental needs for surgical imaging around the world.

ULTRASOUND.

Our Ultrasound equipment portfolio, digital and AI solutions, and associated service capabilities serve customers across five clinical areas: Radiology and Primary Care, Women’s Health, Cardiovascular, Point of Care and Handheld, and Surgical Visualization and Guidance:

- Cardiovascular Ultrasound is used in the diagnosis, treatment, and monitoring of patients with suspected or known heart disease.

Diagnostic exams assess the structure and function of the heart.

Our Ultrasound solutions are also used for guidance during interventional, electrophysiology, and surgical procedures.

- Point of Care and Handheld Ultrasound technologies are portable devices that produce high-quality images, whether in a hospital, ambulance, or remote geographic location.

Clinicians use our Point of Care and Handheld Ultrasound devices to diagnose, monitor, and treat patients’ conditions throughout various care pathways to help improve outcomes while also reducing procedure time and required resources.

Our portfolio contains consoles, laptops, and handheld devices.

- Our suite of Surgical Visualization and Guidance products helps surgeons visualize anatomy and lesions, guide interventions, and navigate inside the human body.

Intraoperative imaging expands the use of ultrasound beyond diagnostics by providing real-time information throughout surgical procedures that can be used to confirm or amend surgical plans, monitor progress, and validate the execution of a procedure.

- Anesthesia and Respiratory Care products offer life support solutions via ventilation technology.

Our respiratory devices are designed to ventilate critically ill patients, generally in ICUs.

We employ approximately 10,300 engineers and scientists worldwide, including hardware, systems, and software engineers and personnel focused on clinical research.

See Note 18, “Supplemental Financial Information” for further information.

- Win together and have fun.

A key pillar of our talent strategy is senior management-led annual organization and talent reviews focused on critical roles, succession plans, and talent development.

We have approximately 1,000 union-represented manufacturing colleagues in the United States, approximately 700 of whom are covered by four-year collective bargaining agreements that were ratified in 2023 and expire in June 2027.

ENVIRONMENTAL, SOCIAL, AND GOVERNANCE

- Promoting inclusion and diversity across the enterprise;

Sales of medical devices and pharmaceuticals outside of these regions are subject to requirements that vary from country to country.

This requires, among other things, receiving specific marketing authorization from the appropriate regulatory authorities, and maintaining our Quality Management System, which is compliant with the applicable local regulatory requirements, and ISO 13485 certification that is recognized by many regulators.

The International Medical Device Regulators Forum, which includes a number of country regulators, has implemented a global approach to auditing medical device manufacturers.

The Medical Device Single Audit Program (“MDSAP”) provides for a single annual audit of a medical device manufacturer by a MDSAP-recognized auditing organization to satisfy the requirements of ISO 13485 and the regulatory requirements of the authorities that participate in MDSAP (currently the U.S., Canada, Australia, Brazil, and Japan).

While the U.S. Food and Drug Administration (“FDA”) accepts MDSAP audit reports as a substitute for routine agency inspections, it considers the following types of inspections to fall outside the scope of MDSAP: for-cause or compliance follow-up inspections; pre-approval or post-approval inspections; and inspections to assess compliance with Electronic Product and Radiation Control regulations, which apply to Molecular Imaging, X-ray, Women’s Health, Interventional, and Surgery products.

UNITED STATES OF AMERICA.

*Food and Drug Law*

Under the Food, Drug, and Cosmetic Act (“FDCA”), we must comply with regulations governing the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale, servicing, and marketing of medical products, including medical devices and pharmaceuticals.

U.S. FDA product approvals and clearances may be withdrawn or suspended if compliance with regulations is not maintained or if product issues are discovered.

Some of our products are also subject to the Radiation Control for Health and Safety Act and the Electronic Product and Radiation Control Regulations, administered by the FDA, which imposes performance standards, record keeping, reporting, product testing, and product labeling requirements on radiation-emitting electronic products, such as X-ray devices.

We must also comply with the Mammography Quality Standards Act for our mammography products.

Further, clinical studies of medical devices and pharmaceuticals are subject to regulation and inspection.

*Devices*

The FDCA classifies medical devices into three classes based on risk, including Class I (lowest risk), Class II (moderate risk), and Class III (highest risk), with more stringent regulatory requirements applicable to higher-risk devices.

For the fiscal year ended December 31, [removed: 2023][added: 2024]

[removed: ][added: ]

The aggregate market value of the outstanding common stock of the Registrant held by non-affiliates as of June [removed: 30, 2023,] [added: 28, 2024,] the last [added: business] day of the registrants most recently completed second fiscal quarter, was approximately [removed: $32] [added: $33] billion.

There were [removed: 455,357,229] [added: 457,298,310] shares of common stock with a par value of $0.01 per share outstanding as of [removed: January 30, 2024.][added: February 6, 2025.]

The definitive proxy statement relating to the registrant’s Annual Meeting of [removed: Shareholders,] [added: Stockholders,] to be held May [removed: 21, 2024,] [added: 28, 2025,] is incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described therein.

| [Forward-Looking [removed: Statements](#i221eafb883df4809b0de60c20b424759_22)] [added: Statements](#ic5f48a2b80264b159361fdd8ef5e37cf_19)] | | | | | | [removed: [3](#i221eafb883df4809b0de60c20b424759_22)] [added: [3](#ic5f48a2b80264b159361fdd8ef5e37cf_19)] | | |

| [Item [removed: 1A.](#i221eafb883df4809b0de60c20b424759_184)] [added: 1A.](#ic5f48a2b80264b159361fdd8ef5e37cf_172)] | | | [Risk [removed: Factors](#i221eafb883df4809b0de60c20b424759_184)] [added: Factors](#ic5f48a2b80264b159361fdd8ef5e37cf_172)] | | | [removed: [15](#i221eafb883df4809b0de60c20b424759_184)] [added: [13](#ic5f48a2b80264b159361fdd8ef5e37cf_172)] | | |

| [Item [removed: 1B.](#i221eafb883df4809b0de60c20b424759_187)] [added: 1B.](#ic5f48a2b80264b159361fdd8ef5e37cf_175)] | | | [Unresolved Staff [removed: Comments](#i221eafb883df4809b0de60c20b424759_187)] [added: Comments](#ic5f48a2b80264b159361fdd8ef5e37cf_175)] | | | [removed: [44](#i221eafb883df4809b0de60c20b424759_187)] [added: [35](#ic5f48a2b80264b159361fdd8ef5e37cf_175)] | | |

| [Item [removed: 3.](#i221eafb883df4809b0de60c20b424759_193)] [added: 3.](#ic5f48a2b80264b159361fdd8ef5e37cf_136)] | | | [Legal [removed: Proceedings](#i221eafb883df4809b0de60c20b424759_193)] [added: Proceedings](#ic5f48a2b80264b159361fdd8ef5e37cf_136)] | | | [removed: [45](#i221eafb883df4809b0de60c20b424759_193)] [added: [36](#ic5f48a2b80264b159361fdd8ef5e37cf_136)] | | |

| [Item [removed: 4.](#i221eafb883df4809b0de60c20b424759_157)] [added: 4.](#ic5f48a2b80264b159361fdd8ef5e37cf_148)] | | | [Mine Safety [removed: Disclosures](#i221eafb883df4809b0de60c20b424759_157)] [added: Disclosures](#ic5f48a2b80264b159361fdd8ef5e37cf_148)] | | | [removed: [45](#i221eafb883df4809b0de60c20b424759_157)] [added: [36](#ic5f48a2b80264b159361fdd8ef5e37cf_148)] | | |

| [Item [removed: 5.](#i221eafb883df4809b0de60c20b424759_199)] [added: 5.](#ic5f48a2b80264b159361fdd8ef5e37cf_184)] | | | [Market for [removed: Registrant](#i221eafb883df4809b0de60c20b424759_199)[’](#i221eafb883df4809b0de60c20b424759_199)[s] [added: Registrant’s] Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i221eafb883df4809b0de60c20b424759_199)] [added: Securities](#ic5f48a2b80264b159361fdd8ef5e37cf_184)] | | | [removed: [45](#i221eafb883df4809b0de60c20b424759_199)] [added: [36](#ic5f48a2b80264b159361fdd8ef5e37cf_184)] | | |

| [Item [removed: 7.](#i221eafb883df4809b0de60c20b424759_106)] [added: 7.](#ic5f48a2b80264b159361fdd8ef5e37cf_97)] | | | [removed: [Management](#i221eafb883df4809b0de60c20b424759_106)[’](#i221eafb883df4809b0de60c20b424759_106)[s] [added: [Management’s] Discussion and Analysis of Financial Condition and Results of [removed: Operation](#i221eafb883df4809b0de60c20b424759_106)s] [added: Operation](#ic5f48a2b80264b159361fdd8ef5e37cf_97)[s](#ic5f48a2b80264b159361fdd8ef5e37cf_97)] | | | [removed: [47](#i221eafb883df4809b0de60c20b424759_106)] [added: [38](#ic5f48a2b80264b159361fdd8ef5e37cf_97)] | | |

| [Item [removed: 7A.](#i221eafb883df4809b0de60c20b424759_283)] [added: 7A.](#ic5f48a2b80264b159361fdd8ef5e37cf_196)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#i221eafb883df4809b0de60c20b424759_283)] [added: Risk](#ic5f48a2b80264b159361fdd8ef5e37cf_196)] | | | [removed: [62](#i221eafb883df4809b0de60c20b424759_283)] [added: [54](#ic5f48a2b80264b159361fdd8ef5e37cf_196)] | | |

| [Item [removed: 8.](#i221eafb883df4809b0de60c20b424759_25)] [added: 8.](#ic5f48a2b80264b159361fdd8ef5e37cf_22)] | | | [Financial Statements and Supplementary [removed: Data](#i221eafb883df4809b0de60c20b424759_25)] [added: Data](#ic5f48a2b80264b159361fdd8ef5e37cf_22)] | | | [removed: [64](#i221eafb883df4809b0de60c20b424759_25)] [added: [56](#ic5f48a2b80264b159361fdd8ef5e37cf_22)] | | |

| [Item [removed: 9.](#i221eafb883df4809b0de60c20b424759_286)] [added: 9.](#ic5f48a2b80264b159361fdd8ef5e37cf_262)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i221eafb883df4809b0de60c20b424759_286)] [added: Disclosure](#ic5f48a2b80264b159361fdd8ef5e37cf_262)] | | | [removed: [116](#i221eafb883df4809b0de60c20b424759_286)] [added: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_262)] | | |

| [Item [removed: 9A.](#i221eafb883df4809b0de60c20b424759_196)] [added: 9A.](#ic5f48a2b80264b159361fdd8ef5e37cf_133)] | | | [Controls and [removed: Procedures](#i221eafb883df4809b0de60c20b424759_196)] [added: Procedures](#ic5f48a2b80264b159361fdd8ef5e37cf_133)] | | | [removed: [116](#i221eafb883df4809b0de60c20b424759_196)] [added: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_133)] | | |

| [Item [removed: 9B.](#i221eafb883df4809b0de60c20b424759_289)] [added: 9B.](#ic5f48a2b80264b159361fdd8ef5e37cf_151)] | | | [Other [removed: Information](#i221eafb883df4809b0de60c20b424759_289)] [added: Information](#ic5f48a2b80264b159361fdd8ef5e37cf_151)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_289)] [added: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_151)] | | |

| [Item [removed: 9C.](#i221eafb883df4809b0de60c20b424759_292)] [added: 9C.](#ic5f48a2b80264b159361fdd8ef5e37cf_268)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i221eafb883df4809b0de60c20b424759_292)] [added: Inspections](#ic5f48a2b80264b159361fdd8ef5e37cf_268)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_292)] [added: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_268)] | | |

| [Item [removed: 10.](#i221eafb883df4809b0de60c20b424759_295)] [added: 10.](#ic5f48a2b80264b159361fdd8ef5e37cf_271)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i221eafb883df4809b0de60c20b424759_295)] [added: Governance](#ic5f48a2b80264b159361fdd8ef5e37cf_271)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_295)] [added: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_271)] | | |

| [Item [removed: 11.](#i221eafb883df4809b0de60c20b424759_298)] [added: 11.](#ic5f48a2b80264b159361fdd8ef5e37cf_274)] | | | [Executive [removed: Compensation](#i221eafb883df4809b0de60c20b424759_298)] [added: Compensation](#ic5f48a2b80264b159361fdd8ef5e37cf_274)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_298)] [added: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_274)] | | |

| [Item [removed: 12.](#i221eafb883df4809b0de60c20b424759_301)] [added: 12.](#ic5f48a2b80264b159361fdd8ef5e37cf_277)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i221eafb883df4809b0de60c20b424759_301)] [added: Matters](#ic5f48a2b80264b159361fdd8ef5e37cf_277)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_301)] [added: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_277)] | | |

| [Item [removed: 13.](#i221eafb883df4809b0de60c20b424759_304)] [added: 13.](#ic5f48a2b80264b159361fdd8ef5e37cf_280)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i221eafb883df4809b0de60c20b424759_304)] [added: Independence](#ic5f48a2b80264b159361fdd8ef5e37cf_280)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_304)] [added: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_280)] | | |

| [Item [removed: 14.](#i221eafb883df4809b0de60c20b424759_307)] [added: 14.](#ic5f48a2b80264b159361fdd8ef5e37cf_283)] | | | [Principal Accountant Fees and [removed: Services](#i221eafb883df4809b0de60c20b424759_307)] [added: Services](#ic5f48a2b80264b159361fdd8ef5e37cf_283)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_307)] [added: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_283)] | | |

| [Item [removed: 15.](#i221eafb883df4809b0de60c20b424759_310)] [added: 15.](#ic5f48a2b80264b159361fdd8ef5e37cf_286)] | | | [Exhibits and Financial Statement [removed: Schedules](#i221eafb883df4809b0de60c20b424759_310)] [added: Schedules](#ic5f48a2b80264b159361fdd8ef5e37cf_286)] | | | [removed: [117](#i221eafb883df4809b0de60c20b424759_310)] [added: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_286)] | | |

| [Item [removed: 16.](#i221eafb883df4809b0de60c20b424759_313)] [added: 16.](#ic5f48a2b80264b159361fdd8ef5e37cf_289)] | | | [Form 10-K [removed: Summary](#i221eafb883df4809b0de60c20b424759_313)] [added: Summary](#ic5f48a2b80264b159361fdd8ef5e37cf_289)] | | | [removed: [120](#i221eafb883df4809b0de60c20b424759_313)] [added: [111](#ic5f48a2b80264b159361fdd8ef5e37cf_289)] | | |

These forward-looking statements may include, but are not limited to, statements about our business; [removed: information related to our business segment portfolios and strategies; human capital management and environmental, social, and governance (“ESG”) strategies and initiatives;] financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows; the impacts of macroeconomic and market conditions and volatility on our business operations, financial results, and financial position and on supply chains and the world economy; our [removed: strategy, innovation, and investments, including research and development activities; our] cost structure; our funding and liquidity; the impacts on our business of manufacturing, sourcing, and supply chain management; the Russia and Ukraine conflict; our operations as a stand-alone company; and risks related to foreign currency exchange, interest rates, and commodity price volatility.

Factors that could cause our actual results to differ materially from those described in our forward-looking statements include, but are not limited to, operating in highly competitive markets; [removed: our ability to successfully complete strategic transactions; the actions or inactions] [added: global geopolitical and economic instability, including as a result] of [removed: third parties with whom we partner] [added: the conflict between Ukraine] and [added: Russia, tensions in] the [removed: various collaboration, licensing,] [added: Middle East,] and [removed: other partnerships] [added: changes in trade] and [removed: alliances we have with third parties;] [added: tariff policy; public health crises, epidemics, and pandemics, and their effects on our business; changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers;] demand for our products, services, or solutions and factors that affect that demand; [added: the delayed China stimulus and the ongoing anti-corruption campaign; our ability to control increases in healthcare costs and any subsequent effect on demand for our products, services, or solutions; our ability to successfully complete strategic transactions; the impacts related to our increasing focus on and investment in cloud, edge computing, artificial intelligence (“AI”), and software offerings;] management of our supply chain and our ability to cost-effectively secure the materials we need to operate our business; disruptions in our operations; [removed: changes in third-party and government reimbursement processes, rates, contractual relationships, and mix of public and private payers, including related to government shutdowns; our ability to attract and/or retain key personnel and qualified employees; global geopolitical and economic instability, including as a result of] the [removed: conflict between Ukraine] [added: actions or inactions of third parties with whom we partner] and [removed: Russia,] the [removed: conflict in Israel and surrounding areas,] [added: various collaboration, licensing,] and [removed: the actions in the Red Sea region; public health crises, epidemics,] [added: other partnerships] and [removed: pandemics, such as] [added: alliances we have with third parties;] the [removed: Coronavirus Disease 2019 (“COVID-19”) and their effects on our business;] [added: impact of potential information technology (“IT”), cybersecurity, or data security breaches;] maintenance and protection of our intellectual property [removed: (“IP”)] rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; [removed: the impact of potential information technology, cybersecurity, or data security breaches;] [added: our ability to attract and/or retain key personnel and qualified employees; environmental, social, and governance (“ESG”) matters;] compliance with the various legal, regulatory, tax, privacy, and other laws to which we are subject, such as the Foreign Corrupt Practices Act [removed: (the “FCPA”)] and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; [removed: our ability to control increases in healthcare costs and any subsequent effect on demand for our products, services, or solutions;] the [removed: impacts related to our increasing focus on and investment in cloud, edge, artificial intelligence (“AI”), and software offerings; the] impact of potential product liability claims; [removed: ESG matters;] our [removed: ability to operate effectively as an independent, publicly traded company; and our] level of indebtedness, as well as our general ability to comply with covenants under our debt instruments, and any related effect on our [removed: business.][added: business; and our ability to operate effectively as an independent, publicly traded company.]

Please also see [removed: the] [added: Item 1A,] “Risk Factors” [removed: section] of this Annual Report on Form 10-K filed with the United States [removed: (“U.S.”)] Securities and Exchange Commission (“SEC”) and any updates or amendments we make in future filings.

| [Item 1.](#ic5f48a2b80264b159361fdd8ef5e37cf_169) | | | [Business](#ic5f48a2b80264b159361fdd8ef5e37cf_169) | | | [4](#ic5f48a2b80264b159361fdd8ef5e37cf_169) | | |

| [Item 1C.](#ic5f48a2b80264b159361fdd8ef5e37cf_178) | | | [Cybersecurity](#ic5f48a2b80264b159361fdd8ef5e37cf_178) | | | [35](#ic5f48a2b80264b159361fdd8ef5e37cf_178) | | |

| [Item 2.](#ic5f48a2b80264b159361fdd8ef5e37cf_181) | | | [Properties](#ic5f48a2b80264b159361fdd8ef5e37cf_181) | | | [36](#ic5f48a2b80264b159361fdd8ef5e37cf_181) | | |

| [Item 6.](#ic5f48a2b80264b159361fdd8ef5e37cf_187) | | | [\[Reserved\]](#ic5f48a2b80264b159361fdd8ef5e37cf_187) | | | [37](#ic5f48a2b80264b159361fdd8ef5e37cf_187) | | |

| [Signatures](#ic5f48a2b80264b159361fdd8ef5e37cf_292) | | | | | | [112](#ic5f48a2b80264b159361fdd8ef5e37cf_292) | | |

| [Item 1.](#i221eafb883df4809b0de60c20b424759_181) | | | [Business](#i221eafb883df4809b0de60c20b424759_181) | | | [4](#i221eafb883df4809b0de60c20b424759_181) | | |

| [I](#i221eafb883df4809b0de60c20b424759_1149)[tem 1C.](#i221eafb883df4809b0de60c20b424759_1149) | | | [C](#i221eafb883df4809b0de60c20b424759_1149)[ybersecurity](#i221eafb883df4809b0de60c20b424759_1149) | | | [44](#i221eafb883df4809b0de60c20b424759_1149) | | |

| [Item 2.](#i221eafb883df4809b0de60c20b424759_190) | | | [Properties](#i221eafb883df4809b0de60c20b424759_190) | | | [45](#i221eafb883df4809b0de60c20b424759_190) | | |

| [Item 6.](#i221eafb883df4809b0de60c20b424759_202) | | | [\[](#i221eafb883df4809b0de60c20b424759_202)[Reserved](#i221eafb883df4809b0de60c20b424759_202)[\]](#i221eafb883df4809b0de60c20b424759_202) | | | [46](#i221eafb883df4809b0de60c20b424759_202) | | |

| [Signatures](#i221eafb883df4809b0de60c20b424759_316) | | | | | | [121](#i221eafb883df4809b0de60c20b424759_316) | | |

[removed: We describe whether and how cybersecurity-related risks could materially affect our business] [added: “Risk Factors”] under the heading [removed: “Increased] [added: *“Increased] cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted [removed: computer] [added: cyber] crimes pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our [removed: business” under Item 1A.][added: business.”*]

The Audit Committee received reports from our Chief Information Officer (“CIO”) and/or CISO [removed: four] [added: five] times in [removed: 2023.][added: 2024.]

The CISO works closely with the CIO, Chief Privacy Officer (“CPO”), and other members of the legal team who report to the General [removed: Counsel] [added: Counsel,] to review the cybersecurity program while monitoring global data protection regulations and cyber security laws.

To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company, including its business strategy, results of operations, or financial condition.

However, despite our security measures, there can be no assurance that the Company, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us.

We describe whether and how cybersecurity-related risks could materially affect our business in item 1A.

“Risk Factors.”

We have 43 manufacturing facilities, of which [removed: 31] [added: 30] are owned.

We have [removed: 16] [added: 15] manufacturing facilities located in the United States and [removed: 27] [added: 28] located outside of the United States, including in China, India, Israel, Mexico, Brazil, Austria, Denmark, France, Germany, Ireland, the Netherlands, Norway, Sweden, Finland, South Korea, and Japan.

We declared and paid a quarterly dividend of $0.03 per share to our stockholders of record for the first, second, and third quarter of [removed: 2023.][added: 2024.]

In the fourth quarter of [removed: 2023,] [added: 2024,] we declared a dividend of [removed: $0.03] [added: $0.035 per share] to be paid in the first quarter of [removed: 2024.][added: 2025.]

STOCK PERFORMANCE [removed: GRAPH][added: GRAPH.]

The following graph compares the total return on the Company’s common stock for the last [removed: 12] [added: 24] months with the Standard & Poor’s [removed: (“S&P”)] 500 [added: (“S&P 500”)] and S&P 500 Healthcare indices.

[removed: ][added: ]

PRINCIPAL MARKET.

STOCKHOLDERS.

There were 189,289 stockholders of record of GE HealthCare common stock as of February 6, 2025.

DIVIDENDS.

PRINCIPAL MARKET

SHAREHOLDERS

There were 198,387 shareholders of record of GE HealthCare common stock as of January 30, 2024.

DIVIDENDS

| [Report of Independent Registered Public Accounting Firm - Deloitte & Touche LLP (PCAOB ID [removed: No.](#i221eafb883df4809b0de60c20b424759_220)] [added: No.](#ic5f48a2b80264b159361fdd8ef5e37cf_202)] 34) | | | [removed: [65](#i221eafb883df4809b0de60c20b424759_220)] [added: [57](#ic5f48a2b80264b159361fdd8ef5e37cf_202)] | | |

| [Consolidated [removed: and](#i221eafb883df4809b0de60c20b424759_31) [Combined] [added: and Combined] Statements of [removed: Income](#i221eafb883df4809b0de60c20b424759_31)] [added: Income](#ic5f48a2b80264b159361fdd8ef5e37cf_28)] | | | [removed: [68](#i221eafb883df4809b0de60c20b424759_31)] [added: [60](#ic5f48a2b80264b159361fdd8ef5e37cf_28)] | | |

| [Consolidated [removed: and](#i221eafb883df4809b0de60c20b424759_34) [Combined] [added: and Combined] Statements of Comprehensive [removed: Income](#i221eafb883df4809b0de60c20b424759_34) [](#i221eafb883df4809b0de60c20b424759_34)[(](#i221eafb883df4809b0de60c20b424759_34)[L](#i221eafb883df4809b0de60c20b424759_34)[o](#i221eafb883df4809b0de60c20b424759_34)[s](#i221eafb883df4809b0de60c20b424759_34)[s](#i221eafb883df4809b0de60c20b424759_34)[)](#i221eafb883df4809b0de60c20b424759_34)] [added: Income (Loss)](#ic5f48a2b80264b159361fdd8ef5e37cf_31)] | | | [removed: [69](#i221eafb883df4809b0de60c20b424759_34)] [added: [61](#ic5f48a2b80264b159361fdd8ef5e37cf_31)] | | |

| [removed: [Consolidated and](#i221eafb883df4809b0de60c20b424759_37) [Combined] [added: Consolidated] Statements of Financial [removed: Position](#i221eafb883df4809b0de60c20b424759_37)] [added: Position] | | | [removed: [70](#i221eafb883df4809b0de60c20b424759_37)] | | | [added: | | |]

| [removed: [Consolidated and](#i221eafb883df4809b0de60c20b424759_226) [Combined] [added: Consolidated and Combined] Statements of Changes in [removed: Equity](#i221eafb883df4809b0de60c20b424759_226)] [added: Equity] | | | [removed: [71](#i221eafb883df4809b0de60c20b424759_226)] | | | [added: | | | | | | | | | | | | | | | | | | | | | | | | | | |]

| [removed: [Consolidated and](#i221eafb883df4809b0de60c20b424759_43) [Combined Statements] [added: [Consolidated](#ic5f48a2b80264b159361fdd8ef5e37cf_40) [a](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[n](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[d](#ic5f48a2b80264b159361fdd8ef5e37cf_40) [](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[Combined](#ic5f48a2b80264b159361fdd8ef5e37cf_40) [](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[Statements] of Cash [removed: Flows](#i221eafb883df4809b0de60c20b424759_43)] [added: Flows](#ic5f48a2b80264b159361fdd8ef5e37cf_40)] | | | [removed: [72](#i221eafb883df4809b0de60c20b424759_43)] [added: [64](#ic5f48a2b80264b159361fdd8ef5e37cf_40)] | | |

[removed: | [Notes to the](#i221eafb883df4809b0de60c20b424759_46) [Consolidated and](#i221eafb883df4809b0de60c20b424759_46) [Combined Financial Statements](#i221eafb883df4809b0de60c20b424759_46) | | | [73](#i221eafb883df4809b0de60c20b424759_46) | | |][added: NOTES TO THE CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS]

| [Note [removed: 1](#i221eafb883df4809b0de60c20b424759_46)[.](#i221eafb883df4809b0de60c20b424759_46) [Organization] [added: 1. Organization] and Basis of [removed: Presentation](#i221eafb883df4809b0de60c20b424759_46)] [added: Presentation](#ic5f48a2b80264b159361fdd8ef5e37cf_43)] | | | [removed: [73](#i221eafb883df4809b0de60c20b424759_46)] [added: [65](#ic5f48a2b80264b159361fdd8ef5e37cf_43)] | | |

| [Note [removed: 2](#i221eafb883df4809b0de60c20b424759_232)[.](#i221eafb883df4809b0de60c20b424759_232) [Summary] [added: 2. Summary] of Significant Accounting [removed: Policies](#i221eafb883df4809b0de60c20b424759_232)] [added: Policies](#ic5f48a2b80264b159361fdd8ef5e37cf_205)] | | | [removed: [74](#i221eafb883df4809b0de60c20b424759_232)] [added: [66](#ic5f48a2b80264b159361fdd8ef5e37cf_205)] | | |

| [Note [removed: 3](#i221eafb883df4809b0de60c20b424759_49)[.](#i221eafb883df4809b0de60c20b424759_49) [Revenue Recognition](#i221eafb883df4809b0de60c20b424759_49)] [added: 3. Revenue Recognition](#ic5f48a2b80264b159361fdd8ef5e37cf_46)] | | | [removed: [83](#i221eafb883df4809b0de60c20b424759_49)] [added: [75](#ic5f48a2b80264b159361fdd8ef5e37cf_46)] | | |

| [Note [removed: 4](#i221eafb883df4809b0de60c20b424759_52)[.](#i221eafb883df4809b0de60c20b424759_52) [Segment] [added: 4. Segment] and Geographical [removed: Information](#i221eafb883df4809b0de60c20b424759_52)] [added: Information](#ic5f48a2b80264b159361fdd8ef5e37cf_49)] | | | [removed: [84](#i221eafb883df4809b0de60c20b424759_52)] [added: [76](#ic5f48a2b80264b159361fdd8ef5e37cf_49)] | | |

| [Note [removed: 5](#i221eafb883df4809b0de60c20b424759_55)[.](#i221eafb883df4809b0de60c20b424759_55) [Receivables](#i221eafb883df4809b0de60c20b424759_55)] [added: 5. Receivables](#ic5f48a2b80264b159361fdd8ef5e37cf_52)] | | | [removed: [86](#i221eafb883df4809b0de60c20b424759_55)] [added: [79](#ic5f48a2b80264b159361fdd8ef5e37cf_52)] | | |

| [Note [removed: 6](#i221eafb883df4809b0de60c20b424759_58)[.](#i221eafb883df4809b0de60c20b424759_58) [Financing Receivables](#i221eafb883df4809b0de60c20b424759_58)] [added: 6. Financing Receivables](#ic5f48a2b80264b159361fdd8ef5e37cf_55)] | | | [removed: [87](#i221eafb883df4809b0de60c20b424759_58)] [added: [80](#ic5f48a2b80264b159361fdd8ef5e37cf_55)] | | |

| [Note [removed: 7](#i221eafb883df4809b0de60c20b424759_247)[.](#i221eafb883df4809b0de60c20b424759_247) [Leases](#i221eafb883df4809b0de60c20b424759_247)] [added: 7. Leases](#ic5f48a2b80264b159361fdd8ef5e37cf_58)] | | | [removed: [87](#i221eafb883df4809b0de60c20b424759_247)] [added: [80](#ic5f48a2b80264b159361fdd8ef5e37cf_58)] | | |

| [Note [removed: 8](#i221eafb883df4809b0de60c20b424759_64)[.](#i221eafb883df4809b0de60c20b424759_64) [Acquisitions,] [added: 8. Acquisitions,] Goodwill, and Other Intangible [removed: Assets](#i221eafb883df4809b0de60c20b424759_64)] [added: Assets](#ic5f48a2b80264b159361fdd8ef5e37cf_61)] | | | [removed: [89](#i221eafb883df4809b0de60c20b424759_64)] [added: [81](#ic5f48a2b80264b159361fdd8ef5e37cf_61)] | | |

| [Note [removed: 9](#i221eafb883df4809b0de60c20b424759_67)[.](#i221eafb883df4809b0de60c20b424759_67) [Borrowings](#i221eafb883df4809b0de60c20b424759_67)] [added: 9. Borrowings](#ic5f48a2b80264b159361fdd8ef5e37cf_64)] | | | [removed: [90](#i221eafb883df4809b0de60c20b424759_67)] [added: [83](#ic5f48a2b80264b159361fdd8ef5e37cf_64)] | | |

| [Note [removed: 10](#i221eafb883df4809b0de60c20b424759_70)[.](#i221eafb883df4809b0de60c20b424759_70) [Postretirement] [added: 10. Postretirement] Benefit [removed: Plans](#i221eafb883df4809b0de60c20b424759_70)] [added: Plans](#ic5f48a2b80264b159361fdd8ef5e37cf_6597069768003)] | | | [removed: [91](#i221eafb883df4809b0de60c20b424759_70)] [added: [84](#ic5f48a2b80264b159361fdd8ef5e37cf_6597069768003)] | | |

| [Note [removed: 11](#i221eafb883df4809b0de60c20b424759_73)[.](#i221eafb883df4809b0de60c20b424759_73) [Income Taxes](#i221eafb883df4809b0de60c20b424759_73)] [added: 11. Income Taxes](#ic5f48a2b80264b159361fdd8ef5e37cf_70)] | | | [removed: [98](#i221eafb883df4809b0de60c20b424759_73)] [added: [90](#ic5f48a2b80264b159361fdd8ef5e37cf_70)] | | |

| [Note [removed: 12](#i221eafb883df4809b0de60c20b424759_76)[.](#i221eafb883df4809b0de60c20b424759_76) [Accumulated] [added: 12. Accumulated] Other Comprehensive (Income) [removed: Loss](#i221eafb883df4809b0de60c20b424759_76) [–](#i221eafb883df4809b0de60c20b424759_76) [Net](#i221eafb883df4809b0de60c20b424759_76)] [added: Loss – Net](#ic5f48a2b80264b159361fdd8ef5e37cf_232)] | | | [removed: [102](#i221eafb883df4809b0de60c20b424759_76)] [added: [93](#ic5f48a2b80264b159361fdd8ef5e37cf_232)] | | |

| [Note [removed: 13](#i221eafb883df4809b0de60c20b424759_79)[.](#i221eafb883df4809b0de60c20b424759_79) [Financial] [added: 13. Financial] Instruments and Fair Value [removed: Measurements](#i221eafb883df4809b0de60c20b424759_79)] [added: Measurements](#ic5f48a2b80264b159361fdd8ef5e37cf_76)] | | | [removed: [102](#i221eafb883df4809b0de60c20b424759_79)] [added: [94](#ic5f48a2b80264b159361fdd8ef5e37cf_76)] | | |

| [Note [removed: 14](#i221eafb883df4809b0de60c20b424759_82)[.](#i221eafb883df4809b0de60c20b424759_82) [Commitments,] [added: 14. Commitments,] Guarantees, Product Warranties, and Other Loss [removed: Contingencies](#i221eafb883df4809b0de60c20b424759_82)] [added: Contingencies](#ic5f48a2b80264b159361fdd8ef5e37cf_79)] | | | [removed: [106](#i221eafb883df4809b0de60c20b424759_82)] [added: [98](#ic5f48a2b80264b159361fdd8ef5e37cf_79)] | | |

| [removed: [Note 1](#i221eafb883df4809b0de60c20b424759_88)[6](#i221eafb883df4809b0de60c20b424759_88)[.](#i221eafb883df4809b0de60c20b424759_88) [](#i221eafb883df4809b0de60c20b424759_88)[Share-Based Compensation](#i221eafb883df4809b0de60c20b424759_88)] [added: Share-based compensation] | | | [removed: [109](#i221eafb883df4809b0de60c20b424759_88)] [added: —] | | | [added: — | | | — | | | — | | | 114 | | | — | | | — | | | — | | | — | | | 114 | | |]

| [Note [removed: 1](#i221eafb883df4809b0de60c20b424759_94)[7](#i221eafb883df4809b0de60c20b424759_94)[.](#i221eafb883df4809b0de60c20b424759_94) [](#i221eafb883df4809b0de60c20b424759_94)[Earnings] [added: 17. Earnings] Per [removed: Share](#i221eafb883df4809b0de60c20b424759_94)] [added: Share](#ic5f48a2b80264b159361fdd8ef5e37cf_85)] | | | [removed: [111](#i221eafb883df4809b0de60c20b424759_94)] [added: [102](#ic5f48a2b80264b159361fdd8ef5e37cf_85)] | | |

| [Note [removed: 1](#i221eafb883df4809b0de60c20b424759_97)[8](#i221eafb883df4809b0de60c20b424759_97)[.](#i221eafb883df4809b0de60c20b424759_97) [Supplemental] [added: 18. Supplemental] Financial [removed: Information](#i221eafb883df4809b0de60c20b424759_97)] [added: Information](#ic5f48a2b80264b159361fdd8ef5e37cf_88)] | | | [removed: [111](#i221eafb883df4809b0de60c20b424759_97)] [added: [103](#ic5f48a2b80264b159361fdd8ef5e37cf_88)] | | |

To the [removed: shareholders] [added: stockholders] and the Board of Directors of GE HealthCare Technologies, Inc.

We have audited the accompanying consolidated [removed: and combined] statements of financial position of GE HealthCare Technologies, Inc. (the [removed: “Company”)] [added: "Company")] as of December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] the related consolidated and combined statements of income, comprehensive income (loss), changes in equity, and cash flows, for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] and the related notes (collectively referred to as the [removed: “financial statements”).][added: "financial statements").]

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the [removed: Company’s] [added: Company's] internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in [removed: *Internal] [added: Internal] Control — Integrated Framework [removed: (2013)*] [added: (2013)] issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 6, 2024,] [added: 13, 2025,] expressed an unqualified opinion on the [removed: Company’s] [added: Company's] internal control over financial reporting.

Income Taxes – Valuation Allowance on Deferred Tax [removed: Assets —] [added: Assets —] Refer to Notes 2 and 11 to the financial statements

[removed: To] [added: To] the [removed: shareholders] [added: stockholders] and the Board of Directors of GE HealthCare Technologies [removed: Inc.][added: Inc.]

We have audited the internal control over financial reporting of GE HealthCare Technologies Inc. (the “Company”) as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in [removed: *Internal] [added: Internal] Control — Integrated Framework [removed: (2013)*] [added: (2013)] issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in [removed: *Internal] [added: Internal] Control — Integrated Framework [removed: (2013)*] [added: (2013)] issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, [removed: 2023,] [added: 2024,] of the Company and our report dated February [removed: 6, 2024,] [added: 13, 2025,] expressed an unqualified opinion on those financial statements.

| [added: Segment EBIT] | | | | | | | | | For the years ended December 31 | | | | | | | | | | | |

| (In millions, except per share amounts) | | | | | | | | | | | | [removed: 2023] [added: 2024] | | | [removed: 2022] [added: 2023] | | | [removed: 2021] [added: 2022] | | |

| Sales of products | | | | | | | | | | | | $ | [removed: 13,127] [added: 13,075] | | $ | [removed: 12,044] [added: 13,127] | | $ | [removed: 11,165] [added: 12,044] | |

| Sales of services | | | | | | | | | | | | [removed: 6,425] [added: 6,597] | | | [removed: 6,297] [added: 6,425] | | | [removed: 6,420] [added: 6,297] | | |

| Total revenues | | | | | | | | | | | | [removed: 19,552] [added: 19,672] | | | [removed: 18,341] [added: 19,552] | | | [removed: 17,585] [added: 18,341] | | |

| Cost of products | | | | | | | | | | | | [removed: 8,465] [added: 8,271] | | | [removed: 7,975] [added: 8,465] | | | [removed: 7,196] [added: 7,975] | | |

| Cost of services | | | | | | | | | | | | [removed: 3,165] [added: 3,196] | | | [removed: 3,187] [added: 3,165] | | | [removed: 3,215] [added: 3,187] | | |

| [Notes to the Consolidated and Combined Financial Statements](#ic5f48a2b80264b159361fdd8ef5e37cf_43) | | | [65](#ic5f48a2b80264b159361fdd8ef5e37cf_43) | | |

| [Note 15. Restructuring](#ic5f48a2b80264b159361fdd8ef5e37cf_82) [Activities](#ic5f48a2b80264b159361fdd8ef5e37cf_82) | | | [100](#ic5f48a2b80264b159361fdd8ef5e37cf_82) | | |

| [Note 16. Share-Based Compensation](#ic5f48a2b80264b159361fdd8ef5e37cf_244) | | | [100](#ic5f48a2b80264b159361fdd8ef5e37cf_244) | | |

| [Note 19. Related Parties](#ic5f48a2b80264b159361fdd8ef5e37cf_91) [and Tra](#ic5f48a2b80264b159361fdd8ef5e37cf_91)[nsition Services Agreement](#ic5f48a2b80264b159361fdd8ef5e37cf_91) | | | [106](#ic5f48a2b80264b159361fdd8ef5e37cf_91) | | |

| [Note 2](#ic5f48a2b80264b159361fdd8ef5e37cf_94)[0](#ic5f48a2b80264b159361fdd8ef5e37cf_94)[. Subsequent Events](#ic5f48a2b80264b159361fdd8ef5e37cf_94) | | | [108](#ic5f48a2b80264b159361fdd8ef5e37cf_94) | | |

| February 13, 2025 | | |

| February 13, 2025 | | |

| Pension and Other Postretirement Plans – net of taxes | | | | | | | | | | | | (456) | | | (897) | | | 58 | | |

| Current compensation and benefits | | | 1,521 | | | 1,518 | | |

| Treasury stock, at cost, 291,053 shares as of December 31, 2024 and 0 shares as of December 31, 2023 | | | (25) | | | — | | |

| Issuance of shares under equity awards, net of shares withheld for taxes and other | | | 1 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | |

| Issuance of shares under equity awards, net of shares withheld for taxes and other | | | 2 | | | — | | | — | | | (25) | | | (35) | | | — | | | — | | | — | | | — | | | (60) | | |

| Dividends declared ($0.125 per common share) | | | — | | | — | | | — | | | — | | | — | | | (58) | | | — | | | — | | | — | | | (58) | | |

| Balances as of December 31, 2024 | | | 457 | | | $ | 5 | | — | | | $ | (25) | | $ | 6,583 | | $ | 3,262 | | $ | — | | $ | (1,379) | | $ | 18 | | $ | 8,464 | |

| Net income | | | $ | 2,050 | | $ | 1,614 | | $ | 1,967 | |

| Current compensation and benefits | | | 39 | | | 153 | | | (37) | | |

| Purchases of investments | | | (40) | | | (48) | | | (59) | | |

| Proceeds from stock issued under employee benefit plans | | | 33 | | | 34 | | | — | | |

| Taxes paid related to net share settlement of equity awards | | | (93) | | | (33) | | | — | | |

On April 2, 2024, GE completed the separation of its GE Vernova business into an independent publicly traded company.

In the fourth quarter of 2024, GE sold its remaining ownership of the Company’s outstanding common stock.

Following the share sell-down, GE continues to be reported as a related party due to the nature of our relationship and board member affiliation.

Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers.

Percentages presented are calculated from the underlying whole-dollar amounts.

Additionally on the Consolidated and Combined Statements of Cash Flows, amounts related to purchase of investments previously reported within All other investing activities – net, and amounts related to equity award activity previously reported within All other financing activities – net, have been reclassified to separate lines.

Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting.

The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”).

Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure.

Actual results could differ from these estimates.

Estimated useful lives generally range from 8 to 40 years for buildings, structures and related equipment, 3 to 20 years for machinery and equipment, and 1 to 15 years for leasehold improvements.

Property, plant and equipment is reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable.

In such circumstances, assets are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values.

As of January 1, 2023, GE HealthCare established the assumed pension plans as single-employer plans, but continued to participate in legacy GE multiple-employer postretirement benefit plans sponsored by GE.

On January 1, 2024, we transitioned from the legacy GE multiple-employer postretirement benefit plans to a GE HealthCare sponsored single-employer postretirement benefit plan.

This change did not have an impact on our results of operations or financial position.

*Money Market Funds*

Money market funds are valued using pricing information from the fund managers, quoted on a daily basis, and are considered Level 2 inputs.

*Recent Accounting Pronouncements Reflected in These Consolidated and Combined Financial Statements*

The Company adopted ASU 2023-07 for the year ended December 31, 2024, retrospectively applied to all prior periods presented in the financial statements.

We are currently evaluating the effect that ASU 2023-09 will have on the disclosures in our notes to the financial statements.

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| [Note 15](#i221eafb883df4809b0de60c20b424759_85)[.](#i221eafb883df4809b0de60c20b424759_85) [Restructuring and Other Activities](#i221eafb883df4809b0de60c20b424759_85) [](#i221eafb883df4809b0de60c20b424759_85)[–](#i221eafb883df4809b0de60c20b424759_85) [Net](#i221eafb883df4809b0de60c20b424759_85) | | | [108](#i221eafb883df4809b0de60c20b424759_85) | | |

| [Note 1](#i221eafb883df4809b0de60c20b424759_100)[9](#i221eafb883df4809b0de60c20b424759_100)[.](#i221eafb883df4809b0de60c20b424759_100) [Related Parties](#i221eafb883df4809b0de60c20b424759_100) | | | [114](#i221eafb883df4809b0de60c20b424759_100) | | |

| [Note](#i221eafb883df4809b0de60c20b424759_280) [20](#i221eafb883df4809b0de60c20b424759_280)[.](#i221eafb883df4809b0de60c20b424759_280) [Discontinued Operations](#i221eafb883df4809b0de60c20b424759_280) | | | [116](#i221eafb883df4809b0de60c20b424759_280) | | |

| [Note](#i221eafb883df4809b0de60c20b424759_103) [21](#i221eafb883df4809b0de60c20b424759_103)[.](#i221eafb883df4809b0de60c20b424759_103) [Subsequent Events](#i221eafb883df4809b0de60c20b424759_103) | | | [116](#i221eafb883df4809b0de60c20b424759_103) | | |

| February 6, 2024 | | |

| | | | As of | | | | | |

| Net parent investment | | | — | | | 11,235 | | |

| Balances as of December 31, 2020 | | | — | | | $ | — | | $ | — | | $ | — | | $ | 15,566 | | $ | (839) | | $ | 24 | | $ | 14,751 | |

| Transfers (to) from GE | | | — | | | — | | | — | | | — | | | (8,373) | | | — | | | — | | | (8,373) | | |

| Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes | | | 1 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | |

As of December 31, 2023, GE’s beneficial ownership was approximately 13.5% of the Company’s outstanding common stock.

The following tables are presented in millions of U.S. dollars (“USD”) unless otherwise stated.

The financial statements include certain transactions with GE, which are disclosed as related party transactions.

We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances.

Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.

There have been no material impacts to our accounting estimates as of December 31, 2023 and 2022, or the results for the years ended December 31, 2023, 2022, and 2021, from the COVID-19 pandemic.

The federal COVID-19 Public Health Emergency declaration in the U.S. ended in May 2023, and COVID-19 restrictions have been lifted in many locations globally.

Equipment leased to others under operating leases is depreciated on a straight-line basis over the term of the lease.

Finance lease receivables are tested for impairment as described in the “Financing Receivables” section above.

*Internal-Use Software*

*External Use Software*

The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations.

Similarly, the tax treatment of certain items reflected in the combined financial statements may not be reflected in the consolidated financial statements and tax returns of GE.

Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the stand-alone combined financial statements that may or may not exist in GE’s consolidated financial statements.

For the years prior to the Spin-Off, all income taxes due to or due from GE that had not been settled or recovered by the end of the period are recognized within Net parent investment in the Combined Statement of Financial Position.

Any differences between actual amounts paid or received by the Company and taxes accrued under the separate return method are deemed to be settled and are recognized within Net parent investment in the Combined Statement of Financial Position.

Current obligations for tax in jurisdictions where the Company did not file a consolidated tax return with GE in the pre-Spin-Off period, including certain foreign and certain U.S. state tax jurisdictions, are recorded as accrued liabilities and recognized within All other liabilities in the Combined Statement of Financial Position.

The effects of tax adjustments and settlements with taxing authorities are presented in the consolidated and combined financial statements in the period to which they relate.

Tax benefits not meeting the measurement or realization criteria represent unrecognized tax benefits.

Therefore, the related assets and liabilities are not reflected in the Combined Statement of Financial Position for the year ended December 31, 2022.

The pension plans are now sponsored by GE HealthCare.

For the postretirement plans, GE HealthCare is now a participant in a multiple-employer plan with GE.

*Recent Accounting Pronouncements Reflected in These Consolidated and Combined Financial Statements* In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, *Liabilities – Supplier Finance Programs (Subtopic 405-50)*.

The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented.

The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations.

The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023.

The Company adopted this guidance on January 1, 2023.

In October 2021, the FASB issued ASU No. 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers*.

Under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, the Company [removed: conducted an evaluation of] [added: evaluated] its disclosure controls and procedures as defined [removed: under] [added: in] Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of December 31, [removed: 2023,] [added: 2024,] and that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management has evaluated the effectiveness of the internal [removed: controls] [added: control] over financial reporting, based on the framework and criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and concluded that they were effective as of December 31, [removed: 2023.][added: 2024.]

Therefore, even those internal [removed: controls] [added: control] systems determined to be effective can provide only reasonable assurance with respect to financial statements preparation and reporting.

[removed: In] [added: During] the [removed: fourth] quarter [removed: of 2023,] [added: ended December 31, 2024,] the Company [removed: exited] [added: continued to exit] from various transition [removed: services arrangements] [added: service agreements] with [removed: GE] [added: GE, primarily] related to IT systems that impact financial reporting.

[removed: Responsibility] [added: Consequently, responsibility] for execution of related internal controls transferred to the [removed: Company.][added: Company, including general IT controls in connection with IT environment changes.]

[removed: Besides] [added: Other than] those [removed: previously discussed,] [added: discussed in the preceding sentences,] there were no [removed: other] changes in the Company’s internal control over financial reporting that occurred during the quarter ended December 31, [removed: 2023] [added: 2024] that materially affected or are reasonably likely to materially affect [removed: our] [added: the Company’s] internal control over financial reporting.

Management has evaluated effectiveness of these controls as part of its overall internal control over financial reporting evaluation.

DIRECTOR AND OFFICER TRADING ARRANGEMENTS.

None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.

None.

The information required under this item, with the exception of “Information About Our Executive Officers” and “Ethics and Governance” located under Item [removed: 1] [added: 1, “Business”] of this Annual Report on Form 10-K, is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2023.][added: 2024.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2023.][added: 2024.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2023.][added: 2024.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2023.][added: 2024.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2023.][added: 2024.]

| 2.1 | | | [Separation and Distribution Agreement, dated November 7, 2022, by and between General Electric Company and the Registrant, as amended (incorporated by reference to Exhibit 2.1 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex21.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex21.htm)[s] [added: Registrant’s] Current Report on Form 8-K filed with the SEC on January 4, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex21.htm)† | | |

| 3.1 | | | [Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522314166/d439598dex31.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522314166/d439598dex31.htm)[s] [added: Registrant’s] Current Report on Form 8-K filed with the SEC on December 29, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522314166/d439598dex31.htm) | | |

| 3.2 | | | [Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522314166/d439598dex32.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522314166/d439598dex32.htm)[s] [added: Registrant’s] Current Report on Form 8-K filed with the SEC on December 29, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522314166/d439598dex32.htm) | | |

| 4.1 | | | [Base Indenture, dated as of November 22, 2022, among GE HealthCare Holding LLC, General Electric Company, as guarantor, and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit [removed: 4.1 of General] [added: 4.1](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex41.htm) [to](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex41.htm) [General] Electric Company’s Current Report on Form 8-K filed with the SEC on November 23, 2022).](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex41.htm) | | |

| 4.2 | | | [First Supplemental Indenture, dated as of November 22, 2022, between GE HealthCare Holding LLC and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit [removed: 4.2 of General] [added: 4.2](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex42.htm) [to](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex42.htm) [General] Electric Company’s Current Report on Form 8-K filed with the SEC on November 23, 2022).](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex42.htm) | | |

| [removed: 4.3] [added: 10.3] | | | [removed: [Registration Rights] [added: [Trademark License] Agreement, dated [removed: as of November 22,] [added: December 31,] 2022, [removed: among] [added: by and between General Electric Company and] GE HealthCare [added: Imaging] Holding [removed: LLC, BofA Securities, Inc., and Morgan Stanley & Co. LLC] [added: Inc.] (incorporated by reference [removed: to] [added: into] Exhibit [removed: 4.3 of General Electric Company’s] [added: 10.4 to the Registrant’s] Current Report on Form 8-K filed with the SEC on [removed: November 23, 2022).](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex43.htm)] [added: January 4, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex104.htm)†] | | |

| 4.4 | | | [Description of [removed: Securities](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) [(incorporated] [added: Securities (incorporated] by reference to Exhibit [removed: 4.4 of the Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)[s] [added: 4.4](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) [t](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)[o](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) [the Registrant’s] Annual Report on Form [removed: 10-K](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) [filed] [added: 10-K filed] with [removed: t](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)[he] [added: the] SEC on February 15, [removed: 2023)](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)[.](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)] | | |

| 10.1 | | | [removed: [Transition Services Agreement](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)[,] [added: [Tax Matters Agreement,] dated January 2, 2023, by and between General [removed: Elect](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)[ric] [added: Electric] Company and the [removed: Re](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)[gistrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm) [(incorporated] [added: Registrant (incorporated] by reference to Exhibit [removed: 10.1] [added: 10.2] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)[s current] [added: Registrant’s Current] Report on Form 8-K filed [removed: wi](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)[th](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm) [the] [added: with the] SEC on January 4, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex101.htm)†] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)†] | | |

| 10.2 | | | [removed: [T](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)[ax] [added: [Employee] Matters [removed: Agreement](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)[,] [added: Agreement,] dated January 2, 2023, by and between General Electric [removed: Com](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)[pany] [added: Company] and the Registrant (incorporated by reference to Exhibit [removed: 10.2] [added: 10.3] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)[s] [added: Registrant’s] Current Report on Form 8-K filed with the SEC on January 4, [removed: 2023](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)[).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex102.htm)†] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)] | | |

| [removed: 10.3] [added: 10.4] | | | [removed: [E](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[mployee] [added: [Real Estate] Matters [removed: Agreement](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[, dated](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm) [January] [added: Agreement, dated January] 2, 2023, by and between General [removed: E](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[lectric] [added: Electric] Company and the Registrant (incorporated by reference to Exhibit [removed: 10.3] [added: 10.5] to the [removed: Regist](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[rant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[s] [added: Registrant’s] Current Report on Form 8-K filed with [removed: t](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)[he](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm) [SEC] [added: the SEC] on January 4, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)] | | |

| 10.5 | | | [removed: [R](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[eal Es](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[tate](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm) [Matters Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant] [added: [Form of Indemnification Agreement] (incorporated by [removed: refe](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[rence] [added: reference] to Exhibit [removed: 10.5] [added: 10.7] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[s Current R](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[ep](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)[ort on] [added: Registrant’s] Form [removed: 8-K] [added: 10] filed with the SEC on [removed: January 4, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)] [added: October 11, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522260650/d379971dex107.htm)] | | |

| [removed: 10.6] [added: 10.25*] | | | [removed: [S](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[toc](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[kholder and Regist](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[ration Rights Agreement](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[, dated January 2, 2023, by and between G](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[eneral Electric Company and the Registrant] [added: [GE HealthCare Founders Stock Option Grant Agreement] (incorporated by reference to Exhibit [removed: 10.6] [added: 10.2] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[s] [added: Registrant’s] Current Report on Form [removed: 8](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)[\-K] [added: 8-K] filed with the SEC on [removed: January 4, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex106.htm)†] [added: February 3, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/formofaward2023ltipstockop.htm)] | | |

| [removed: 10.8] [added: 10.6] | | | [Term Loan Agreement, dated as of November 4, 2022, by and among GE HealthCare Holding LLC, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.8 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex108.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex108.htm)[s] [added: Registrant’s] Amendment No.1 to Form 10 filed with the SEC on November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex108.htm) | | |

| [removed: 10.9] [added: 10.7] | | | [364-Day Revolving Credit Agreement, dated as [removed: of](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [December 13](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[3](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[,] [added: of December 1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[4](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[,] by and among GE [removed: HealthCare](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [Technolo](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[gi](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[es Inc.](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[,] [added: HealthCare Technologies Inc.,] the lenders [removed: party](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [thereto](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[,] [added: party thereto,] and Citibank, [removed: N](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[.A.,] [added: N.A.,] as [removed: Administra](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[tive Agent](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[(incorporated] [added: Administrative Agent](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm) [(incorporated] by reference to Exhibit [removed: 10.](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[1](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [to the Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[s](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [F](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[orm 8-K](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [filed] [added: 10.1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm) [the Registrant’s Form 8-K filed] with the SEC [removed: on](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm) [Dec](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[ember 15](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[3](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)[).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000133/gehc8-k_121523xexhibit101.htm)] [added: on December 1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[4](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[).](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)] | | |

| [removed: 10.10] [added: 10.8] | | | [Credit Agreement, dated as of November 4, 2022, by and among the Registrant, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.10 to the Registrant's Amendment No. 1 to Form 10 filed with the SEC on November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1010.htm) | | |

| [removed: 10.11*] [added: 10.9*] | | | [GE HealthCare 2023 Long-Term Incentive [removed: Plan](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm) [](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)[(incorporated] [added: Plan (incorporated] by reference to Exhibit [removed: 10.11 of](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)] [added: 10.11](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)] [the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)[s](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm) [Registration] [added: Registrant’s Registration] Statement on Form S-1 filed with the SEC on December 14, [removed: 2022)](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)[.](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)] [added: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm)] | | |

| [removed: 10.12*] [added: 10.10*] | | | [GE HealthCare Mirror 2022 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.12 of the Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm)[s] [added: 10.12](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm) [the Registrant’s] Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm) | | |

| [removed: 10.13*] [added: 10.11*] | | | [GE HealthCare Mirror 2007 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.13 of the Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm)[s] [added: 10.13](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm) [the Registrant’s] Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm) | | |

| [removed: 10.14*] [added: 10.12*] | | | [GE HealthCare Mirror 1990 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.14 of the Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm)[s] [added: 10.14](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm) [the Registrant’s] Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm) | | |

| [removed: 10.15*] [added: 10.13*] | | | [removed: [O](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm)[ffer] [added: [Offer] Letter with Peter J. [removed: Arduini](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm)[,] [added: Arduini,] dated [removed: J](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm)[une] [added: June] 15, 2021 (incorporated by reference to Exhibit 10.15 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm)[s] [added: Registrant’s] Amendment No. 1 to Form 10 filed with the SEC on November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm) | | |

| [removed: 10.16*] [added: 10.14*] | | | [removed: [A](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[mended] [added: [Amended] Offer [removed: Let](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[ter] [added: Letter] with Peter J. [removed: Arduini](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[, dated](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm) [N](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[ovember] [added: Arduini, dated November] 16, 2022 (incorporated by reference to Exhibit 10.16 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[s A](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[men](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[dment] [added: Registrant’s Amendment] No. 2 to Form 10 filed [removed: wi](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[th] [added: with] the SEC on [removed: N](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm)[ovember] [added: November] 18, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm) | | |

| [removed: 10.17*] [added: 10.20*] | | | [removed: [S](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[ettlement Agreement with K](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[ie](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[ran Murphy](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[, dated December 21, 2021] [added: [GE HealthCare Restoration Plan] (incorporated by reference to Exhibit [removed: 10.16] [added: 10.21] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[s] [added: Registrant’s] Amendment No. [removed: 1](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm) [to] [added: 1 to] Form 10 filed with the SEC on [removed: N](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[ovember] [added: November] 7, [removed: 202](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)[2).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1016.htm)] [added: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1021.htm)] | | |

| [removed: 10.18*] [added: 10.15*] | | | [removed: [O](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)[ffer] [added: [Offer] Letter with [removed: Helmut](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm) [Zodl](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)[, dated](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm) [November 25, 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)[0] [added: Frank R. Jimenez, dated February 4, 2022] (incorporated by reference to Exhibit [removed: 10](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)[.12] [added: 10.13] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)[s] [added: Registrant’s] Quarterly [removed: Report](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm) [on] [added: Report on] Form [removed: 10-Q](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm) [filed] [added: 10-Q filed] with the SEC on April 25, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1012.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm)] | | |

| [removed: 10.19*] [added: 10.16*] | | | [Offer Letter [removed: with](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm) [Frank R. Jimenez](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm)[, dated](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm) [February] [added: with James K. Saccaro, dated May] 4, [removed: 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm) [(incorporated] [added: 2023 (incorporated] by reference to Exhibit [removed: 10.1](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm)[3](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm) [to] [added: 10.2 to] the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on [removed: April] [added: July] 25, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm)†] | | |

| [removed: 10.20*] [added: 10.17*] | | | [Offer Letter [removed: with](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm) [Betty D.](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm) [Larson](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm)[, dated](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm) [January 21, 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm) [(incorporated] [added: with Taha Kass-Hout,](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) [dated September](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) [9](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) [(incor](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[porate](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[d] by reference to Exhibit [removed: 10.1](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm)[4](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm) [to] [added: 10.5 to] the [removed: Registrant’s] [added: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[s] Quarterly Report on Form [removed: 10-Q] [added: 10-](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[Q] filed with the SEC on April [removed: 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1014.htm)†] [added: 30, 2024).](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)] | | |

| [removed: 10.21*] [added: 10.22*] | | | [removed: [O](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm)[ffer Letter with James K. Saccaro, dated May 4, 2023] [added: [GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team] (incorporated by reference [removed: to](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm) [Exhibit 10.2] to [added: Exhibit 10.1 to] the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm)[s] [added: Registrant’s] Quarterly Report on Form 10-Q filed with the SEC on July 25, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm)†] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit101.htm)] | | |

| [removed: 10.22*] [added: 10.29*] | | | [removed: [E](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[mployment Contract with Jan Makela, dated February 2](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[4, 2023] [added: [2023 Global Addendum] (incorporated by reference to Exhibit [removed: 10](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[.15] [added: 10.3] to [removed: t](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[he Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[s](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm) [](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[Quarterly](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm) [Report] [added: the Registrant’s Current Report] on Form [removed: 10-Q](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm) [filed] [added: 8-K filed] with the SEC [removed: on](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm) [Ap](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)[ril 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1015.htm)] [added: on February 3, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/formofawardgehealthcare-gl.htm)] | | |

| 10.23* | | | [removed: [S](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm)[eparation Agreement & Release between the Registra](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm)[nt] [added: [GE HealthCare Non-Employee Director Compensation] and [removed: Helmut Zodl, dated August 18, 2023] [added: Benefits Plan] (incorporated by reference [removed: to](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm) [Exhibit 10.1] to [removed: the](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm) [Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm)[s] [added: Exhibit 10.9 to the Registrant’s] Quarterly Report on Form 10-Q filed with the SEC on [removed: October 31, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000125/gehc3q202310qexhibit101.htm)†] [added: April 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit109.htm)] | | |

| [removed: 10.24*] [added: 10.18*] | | | [removed: [P](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)[erformance Share] [added: [Performance Stock Unit] Grant Agreement for [removed: H. Lawrence Culp](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)[, Jr.](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)[,] [added: Peter J. Arduini,] dated [removed: August 18, 2020] [added: February 23, 2022] (incorporated by reference to Exhibit [removed: 10.17] [added: 10.19] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)[s] [added: Registrant’s] Amendment No. 1 to Form 10 filed with the SEC on [removed: N](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)[ovember] [added: November] 7, [removed: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1017.htm)] [added: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)] | | |

| 10.26* | | | [removed: [P](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[e](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[rformance] [added: [2023 GE HealthCare Restricted] Stock [removed: Unit](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm) [Grant] [added: Unit Grant] Agreement [removed: for Peter J. Arduini, dated February](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm) [23, 2022] (incorporated by reference to Exhibit [removed: 10.19] [added: 10.1] to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[s A](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[men](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[dment No. 1 to] [added: Registrant’s Current Report on] Form [removed: 10 filed](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm) [with] [added: 8-K filed with] the SEC on [removed: Novem](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)[ber 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)] [added: March 3, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000037/formofaward-2023ltiprsugra.htm)] | | |